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ABSTRACT
Phosphatidylinositol 3-kinases (PI3K) are key intracellular signaling molecules. Our
objective was to determine effects o f isoform-selective PI3K inhibitors on osteoclasts.
The following inhibitors were investigated (targets in parentheses): wortmannin and
LY294002 (pan-pllO), PIK75 (a), GDC0941 (a, 5), TGX221 (p), AS252424 (y),
IC87114 (5) and CAL-120 (5). Wortmannin, GDC0941, IC87114 and CAL-120 induced
dramatic retraction o f rat osteoclasts. In contrast, there was no significant retraction in
response to vehicle, PIK75, TGX221 or AS252424. Moreover, wortmannin and CAL120, but not PIK75 or TGX221, disrupted filamentous F-actin belts; and CAL-120
inhibited the formation o f sealing zones. In contrast to their selective actions on
cytoskeletal organization, PIK75, TGX221 and CAL-120 blocked RANKL-stimulated
osteoclast survival. Thus, PI3K8 appears to play a specific role in regulating osteoclast
cytoskeleton. In contrast, multiple PI3K isoforms control osteoclast survival. The PI3K5
isoform, which has more limited tissue distribution than PI3Ka and PI3KP, is an
attractive target for anti-resorptive therapeutics.
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CHAPTER ONE

Introduction
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1.1

Chapter Summary
Osteoblasts (bone forming cells) and osteoclasts (bone resorbing cells) play

essential roles in skeletal development, skeletal remodeling and mineral homeostasis.
The actions o f these two cell types are tightly regulated. Perturbations in the balance
between osteoblasts and osteoclasts result in disease states, such as tumor osteolysis
(bone loss due to cancer), osteoporosis (excess bone resorption) or periodontitis (chronic
inflammation associated with loss of alveolar bone).

Class I phosphatidylinositol-3

kinases (PI3K) have critical roles in a variety o f cellular processes such as metabolism,
differentiation, survival and migration.

Recently developed isoform-selective PI3K

inhibitors show considerable promise for the treatment of inflammatory disease and
cancer, and are making their way into the early phases of clinical trials (Okkenhaug et al.,
2002; Durand et al., 2009; Liu et al., 2009; Cleary & Shapiro, 2010; Lannutti et al.,
2011). This chapter summarizes background information on osteoclastogenesis and bone
remodeling.

Furthermore, the findings from previous studies on PI3K isoform

expression, signaling pathways and functional roles of will be discussed.
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1.2

Bone Physiology

1.2.1

Composition, Structure and Function of Bone
Bone is a specialized connective tissue that functions to protect vital organs, to

serve as a reservoir for ions such as calcium and phosphate, and to serve as a site for
muscle attachment to support locomotion (Marks & Popoff, 1988). Mechanical stimuli
along with local and systemic factors, such as parathyroid hormone (PTH) and calcitonin,
act in concert to maintain bone homeostasis (Harada & Rodan, 2003). Bone is one of the
only tissues in the body that is composed of both organic and inorganic phases. The
inorganic phase of bone is predominantly hydroxyl-apatite [Caio(P0 4 )6(OH)2], however
bone mineral also contains carbonate, fluoride and magnesium referred to, collectively, as
crystalline carbonate-substituted apatite (Rey et al., 1991). The inorganic phase of bone
provides load bearing strength and rigidity to the bone composite.

The organic phase is

composed primarily of type I collagen (-90% ), and trace amounts of type III and V
collagen and other proteins, which provide elasticity and flexibility to bone (Ashhurst et
al., 1990). Fiber organization allows the highest density of collagen per unit volume of
tissue in preferentially orientated structures called lamellae. The lamellae can be parallel
or deposited concentrically surrounding a channel containing blood vessels called a
Haversian system. When there is no preferential organization of collagen fibers, this type
o f bone is called woven bone and occurs during development and fracture healing.
The non-collagenous proteins o f the bone extracellular matrix belong to the
proteoglycan and glycoprotein classes.

The proteoglycans include versican, decorin,

biglycan, hyaluronan; whereas, the glycoproteins include osteonectin, osteopontin, bone
sialoprotein, and osteocalcin (Robey, 1996). These proteins are highly anionic that have
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a high ion-binding capacity and play a role in the fixation of hydroxyl-apatite crystals to
collagen (Rees et al., 2001).
The external part o f bones is formed by a thick and dense layer o f calcified tissue,
called the cortex, which encloses the medullary cavity where hematopoietic bone marrow
is housed. Toward the ends of long bones, the cortex becomes progressively thinner, and
the internal space is filled with a calcified network o f trabeculae, called trabecular bone,
where the bone marrow within the medullary cavity is continuous. The bone surface at
the ends o f bones which take part in a joint are covered in a layer o f articular cartilage,
which acts to separate, lubricate and absorb shock between bones.
Anatomically, there are two types o f bone: flat bones and long bones. Flat bones
are found in the skull, scapula, and mandible; whereas, the tibia, femur, radius, and
humerus are examples o f long bones. These two types arise by intramembranous or
endochrondral, bone formation, respectively.
During

intramembranous

ossification,

mesenchymal

cells

proliferate

and

concentrate within a highly vascularized area of embryonic connective tissue and
differentiate into preosteoblasts and osteoblasts (Hall et al., 1995). These cells synthesize
the osteoid, a non-mineralized bone matrix composed primarily of type I collagen, and
begin to calcify the osteoid in a delayed and irregularly distributed fashion, forming
woven bone. During this process, osteoblasts become entrapped within the matrix and
are then termed osteocytes (Franz-Odendaal et al., 2006). Later this bone is remodeled
and replaced by mature lamellar bone.
During the development o f long bones, the process o f endochondral ossification is
initiated by the differentiation o f mesenchymal stem cells into prechondroblasts and
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chondroblasts, which secrete a collagenous matrix to form cartilage (Mackie et al., 2008).
The chondroblasts that become entrapped within the matrix are then termed chondrocytes
and continue to proliferate. These chondrocytes are arranged into four morphologically
distinct zones adjacent to one another along the growing bone: 1) resting, 2) flattened
proliferating chondrocytes, 3) prehypertrophic chondrocytes and 4) hypertrophic
chondrocytes (Mackie et al., 2008).

Hypertrophic chondrocytes secrete alkaline

phosphatase, which promotes mineralization of the extracellular matrix (Ismail et al.,
2004), and angiogenic factors such as vascular endothelial growth factor (VEGF) to
promote vascular invasion (Miyamoto & Suda, 2003). Osteoblasts form bone on the
remnants o f the calcified cartilage.

In parallel, hypertrophic chondrocytes begin to

undergo apoptosis, and the newly established vessels provide access for osteoclasts,
which resorb the mineralized cartilage, creating a medullary cavity for the bone marrow
(Miyamoto & Suda, 2003).
All bones within the body are continuously being remodeled by osteoblasts and
osteoclasts throughout our lives. It has been proposed that the entire skeleton is replaced
every 10 years. The process o f resorption is relatively faster than the process o f bone
formation, and therefore these processes must be kept in balance or skeletal diseases will
result (Harada & Rodan, 2003). Many signaling networks have been identified that serve
to ensure balanced activity, however some are not well defined.
1.2.2

Regulation of bone formation
There is an established coupling between resorption and formation o f bone.

Although, the signaling pathway for recruitment of mesenchymal cells and osteoblast
precursors is unclear, it may be due to factors released during resorption that lead to
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proliferation and migration o f osteoblast precursors to the bone surface (Manolagas,
2000). It is known that mesenchymal cells concentrate at areas o f bone resorption and
differentiate into cells o f the osteoblast lineage under the control of cytokines and growth
factors such as bone morphogenetic proteins (BMPs) and Wnt ligands (Manolagas,
2000).

Osteoblasts at these sites lay down osteoid that subsequently becomes

mineralized. Following, the majority o f osteoblasts undergo apoptosis, however some
remain on the surface, called lining cells, and some further differentiate into osteocytes
(Manolagas, 2000).
1.2.3

Osteoclastogenesis
Osteoclasts are derived from hematopoietic stem cells in the bone marrow, which

further differentiate into multipotent progenitors (Yin & Li, 2006).

Multipotent

progenitors are capable o f undergoing further differentiation to produce cells of two
different lineages - the common lymphoid progenitor (CLP) or common myeloid
progenitor (CMP). CLP cells produce T cells, B cells and natural killer cells; whereas
CMP

cells

can

differentiate

into

two

further

lineages:

either

the

erythrocyte/megakaryocyte lineage or into the granulocyte/macrophage progenitor
(GMP) (Yin & Li, 2006). The transcription factor PU.l is the earliest known marker of
osteoclast differentiation and is essential for the commitment o f these initial GMP cells
into the monocyte/macrophage cells, which are precursors to osteoclasts (Tondravi et al.,
1997).

Deletion o f PU .l results in severe osteopetrosis in mice due to the absence

macrophages and osteoclasts (Tondravi et al., 1997).

PU.l is important because it

regulates the expression of the macrophage colony stimulating factor (M-CSF) receptor,
c-fms, on early osteoclast precursors and monocytes, which is critical for their survival.
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Monocytic cells and osteoclast precursors exit the bone marrow and enter the
circulation until they are recruited to the bone surface. Under normal conditions, or at
sites o f damage and tissue injury, stromal and immune cells release chemoattractant
agents that recruit osteoclast precursors to the bone surface. M-CSF, receptor activator of
nuclear factor

kB

ligand (RANKL), sphingosine-1 phosphate (SIP) and VEGF are all

known chemoattractants o f osteoclast precursor cells (Henriksen et al., 2003; Ishii et al.,
2009). The process of osteoclast differentiation is summarized Fig. 1.1.
Osteoclast precursor proliferation and resistance to apoptosis are induced by MCSF binding to its receptor c-fms (Arai et al., 1999). c-fms is a tyrosine kinase that
autophosphorylates

itself upon

ligand

binding,

which

activates

ERK1/2

and

phosphatidylinositol-3 kinase (PI3K) pathways that drive the transcription of c-Fos and
RANK to promote osteoclastogenesis, and Bcl-2 and Bcl-xl to promote survival
(Teitelbaum, 2007).
The primary driver o f osteoclastogenesis is receptor activator of nuclear factor kB
ligand (RANKL) (Roodman, 1996; Suda et al., 2001). RANKL is a membrane-bound or
soluble protein produced by bone marrow stromal cells, osteoblasts and T-cells. As a
response to RANKL binding to its receptor, activator of nuclear factor kB (RANK), post
mitotic, committed osteoclast precursors fuse to yield large multinucleated cells. Bone
resorption is completely abolished in R AN K A mice due to lack o f osteoclasts (Lacey et
al., 1998). RANK is related to the tumor necrosis factor (TNF) receptor and has a long
cytoplasmic tail that complexes with signaling molecules, such as TNF receptorassociated factor 6 (TRAF6) and activates NF-kB, Jun N-terminal kinase (JNK),
mitogen-activated protein kinases (MAPK) p38 and Ca /calmodulin pathways that
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1

Figure 1.1 Schematic diagram illustrating osteoclastogenesis from hematopoietic stem
cells. Abbreviations: CLP, common lymphoid progenitor; CMP, common myeloid
progenitor; GMP, granulocyte/macrophage progenitor; M-CSF, macrophage colony
stimulating factor; OCP, osteoclast precursor; RANKL, receptor activator of nuclear factor
k B ligand; NF- k B, nuclear factor kappa B; NFAT, nuclear factor o f activated T cells; DCSTAMP, dendritic cell-specific transmembrane protein; MCP-1, monocyte chemotactic
protein 1; MKEP, megakaryocyte erythroid progenitor.
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leads to activation o f the transcription factor NFATcl (Asagiri & Takayanagi, 2007).
NFATcl is the primary driver o f expression o f many genes required for osteoclast
function and regulation, including cathepsin K, P3 integrin, TRAF6 and the calcitonin
receptor (Ikeda et al., 2004).

The transcription factor c-Fos drives transcription of

NFATcl. Notably, c-Fos'~ mice lack osteoclasts, but not macrophages, and exhibit severe
osteopetrosis (Grigoriadis et al., 1994). NFATcl deletion is embryonic lethal, however
cultured embryonic stem cells from N F A T c l mice do not undergo differentiation into
osteoclasts, indicating NFATcl is required for osteoclastogenesis (Asagiri et al., 2005).
The last and unique step of osteoclastogenesis is the fusion of osteoclast
precursors to become large mature multinucleated osteoclasts. The seven transmembrane
spanning receptor, dendritic cell-specific transmembrane protein (DC-STAMP) (Yagi et
al., 2006) and the monocyte chemotactic protein-1 (MCP-1) have been shown to promote
the fusion of osteoclast precursors into multinucleated osteoclasts (Kim et al., 2005). The
exact process and ligand for DC-STAMP has yet to be elucidated.
Other factors that stimulate osteoclast formation include interleukin-11 (IL-11),
parathyroid hormone-related protein (PTHrP) and prostaglandin E 2, which appear to act
primarily by inducing RANKL expression by osteoblasts (Roodman, 1996).
1.2.4

Osteoclast Attachment
Osteoclast precursors are recruited to the bone surface from blood vessels or

marrow where they attach and fuse together to form multinucleated cells that develop
machinery to resorb bone. Osteoclasts attach to bone via integrins including collagen
integrin receptors called a2pi and a v p i, and a vitronectin receptor called avp3 (Duong et
al., 2000).

p3 knockout mice have dysfunctional osteoclasts and decreased bone
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resorption suggesting that avp3 is the most essential integrin for osteoclast attachment
(McHugh et al., 2000). The avP3 integrins interact with proteins expressing a sequence
o f arginine, glycine and aspartic acid residues (RGD), such as vitronectin, fibronectin,
bone sialoprotein and osteopontin, thereby activating a signaling cascade to prepare the
osteoclast for bone resorption (Teitelbaum, 2007).
Osteoclasts can adhere to several substrates on which they form distinct
filamentous actin (F-actin) containing structures, called podosomes.

Podosomes are

small punctate adhesion structures, each consisting of a core o f F-actin and actinassociated proteins surrounded by integrins and integrin-associated proteins (Saltel et al.,
2008).

Actin is one of the most abundant intracellular proteins that comprise the

microfilament system for cell movement. Actin exists as an individual subunit monomer
known as globular actin (G-actin) and as long filamentous chains of monomers, called Factin.

F-actin and G-actin are dynamically remodelled to allow cell movement and

morphological changes. Osteoclasts exhibit two different actin cytoskeletal organizations
according to the substrate they attach. In vitro, on non-mineralized substrates, such as
glass or plastic, they form clusters o f podosomes, or a band o f podosomes at the
periphery o f the cell, called F-actin belts. On mineralized substrates, such as bone or
calcium phosphate matrices, podosomal units condense, forming a ring in the interior of
the cell, called F-actin rings or sealing zone (Saltel et al., 2008).

In osteoclasts, the

formation o f podosome clusters and rings is microtubule independent; whereas the
podosome belts depend on stabilized acetylated microtubules (Destaing et al., 2003). It
has been observed that osteoclasts degrade bone only within the area defined by F-actin
super structures (Badowski et al., 2008) and that podosomes are essential for extracellular
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matrix degradation and osteoclast migration (Mizutani et al., 2002; Linder &
Aepfelbacher, 2003; Calle et al., 2006).
1.2.5

Bone Resorption
Once osteoclasts adhere to the bone, they form a sealing zone. The sealing zone

has been shown to be associated with actin-related protein (Arp) 2/3 complex, WiskottAldrich Syndrome protein (WASp) and WASp interacting protein (WIP), cortactin,
formin, paxillin, c-src, Pyk2 (proline-rich tyrosine kinase 2), c-cbl, myosin II and
colocalised avp3 integrins (Chabadel et al., 2007; Saltel et al., 2008). Osteoclasts unable
to form this seal are unable to resorb bone (Duong & Rodan, 1998; Mulari et al., 2003a).
The sealing zone gives rise to an enclosed microenvironment between the osteoclast and
bone surface called the resorption lacuna.

The plasma membrane within the

compartment is extensively folded, creating a characteristic feature of the osteoclast,
termed the ruffled border. Within it, the ruffled border o f the osteoclast increases surface
area for the transport o f products for the degradation o f inorganic and organic phases.
Systematically, H+ ions (generated by cytosolic carbonic anhydrase II) via vacuolar
ATPases and passive movement o f Cl' ions via chloride channels are released into the
resorption lacuna to dissolve the inorganic phase, thereby releasing calcium and
phosphate (Zaidi et al., 2003). Normal function of both the C1C7 chloride channels and
vacuolar ATPases are absolutely critical for the breakdown of the mineral (Zaidi et al.,
2003). The pH within the resorption lacuna is approximately 4.5-5 (Teitelbaum & Ross,
2003).

To degrade the organic phase (type I collagen), osteoclasts release

metalloproteinases and lysosomal enzymes, such as cathepsin K, which require an acidic
pH to be functional (Zaidi et al., 2003). Mutation in the cathepsin K gene results in
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dysfunctional osteoclasts and osteopetrosis (Zaidi et a l, 2003). Digested fragments of
matrix proteins are transcytosed from apical to basolateral membranes which is proposed
to occur at the center of the sealing zone (Salo et a l, 1997; Mulari et al., 2003). The
process o f osteoclast resorption is summarized in Fig. 1.2. After a cycle of resorption, the
osteoclast either undergoes apoptosis or moves to a new resorption site.
1.2.5

Regulation of Osteoclasts
Hormones, growth factors and cytokines regulate bone mass directly or indirectly,

through their actions on osteoclasts or osteoblasts.

These factors can influence

differentiation o f precursors, life span of mature cells, among many others effects. This
section will review some o f the important factors that affect osteoclasts and bone mass.
Estrogen - estrogen is a sex steroid produced primarily by a developing follicle in
the ovaries and plays important role in female reproduction. Estrogen is carried in the
blood by albumin, and easily passes through the cell membrane o f target cells where it
binds to a nuclear receptor (estrogen receptor a or P) to promote secondary sex
characteristics (Mauvais-Jarvis, 2010; Heldring et a l, 2007). Estrogen and its analogs
exert a protective effect on the skeleton, which is most apparent by the decrease in bone
density in woman following menopause (Heldring et a l, 2007). Estrogen inhibits the
production of RANKL, and increases the production of osteoprotegerin (OPG - a decoy
receptor which prevents RANKL from binding RANK and stimulating osteoclasts) by
osteoblasts, which express both receptors, a and P (Bord et a l, 2003). Also, estrogen
also can bind directly to osteoclasts through estrogen receptor a to induce apoptosis
(Nakamura et a l, 2007).
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Figure 1.2 Schematic representation of osteoclast resorption on bone. Osteoclasts adhere to
bone via avP3 integrins and form a sealing zone consisting of F-actin and other integrin
binding proteins. Protons (H+) are generated by the activity of carbonic anhydrase II (CAII)
and are transported to the resorption lacuna through V-type Ff ATPases residing in the ruffled
border close to sealing zone. Electrical neutrality is maintained by passively exchanging
chloride ions (Cl ) for bicarbonate (H C 03) at the basolateral membrane. Cl moving into the
cell is transported into the resorption lacuna passively through the anion channel C1C7.
Lysosomal enzymes, such as cathepsin K, are secreted into the resorption lacuna via vesicles
to digest type I collagen and other organic tissue. Organic fragments are then removed by
transcytosis.
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Vitamin D - 1, 25 (0 H)2 vitamin D 3 synthesis requires ultraviolet light to convert
precursor 7-dehydrocholesterol to previtamin D3 in the epidermis (Bouillon et al., 1995).
Vitamin D 3 is then transported and converted in to its biologically active form
l,25(OH)2D3 in the liver and kidney. The major role o f vitamin D in the body is to
regulate Ca2+ and PO43' metabolism through bone, the kidney and intestine. Vitamin D
maintains blood Ca2+ concentrations by absorption in the gastrointestinal tract, release of
calcium stored in bone, and by enhancing reuptake in renal tubules. Vitamin D binds to
its nuclear receptor, vitamin D receptor (VDR) and up regulates alkaline phosphatase
(mineralization) and RANKL expression in osteoblasts (Holick, 2006).

Vitamin D

promotes healthy mineralization, growth and remodeling of bone, and prevents
hypocalcaemia and osteoporosis (Holick, 2007).

Vitamin D deficiency can lead to

rickets in children and osteomalacia in adults (Holick, 2007).
Parathyroid hormone (PTH) - PTH is secreted by the parathyroid gland in
response to low blood concentrations o f calcium.

Interestingly, PTH stimulates bone

formation when administrated intermittently but causes severe bone loss with continuous
administration.

Intermittent dosing promotes healthy mineralization, growth and

remodeling o f bone; whereas continuous dosing increases bone resorption by enhancing
RANKL production by osteoblasts (Malluche et al., 2006).
Calcitonin - Calcitonin is released by parafollicular cells in the thyroid gland in
response to elevated blood concentrations of calcium.

Mature osteoclasts express

calcitonin receptors which are G protein coupled-receptors that bind the 32-amino acid
peptide hormone, calcitonin, leading to inhibition of resorption by osteoclasts
(Warshafsky et al., 1985; Zaidi et al., 2002; Karsdal et al., 2006).
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Transforming Growth F actor-f (TGF-fi) - TGF-P has a fundamental role in the
control o f bone resorption.

TGF-P binds to its serine/threonine kinase receptor on

osteoclast precursors and enhances osteoclastogenesis and bone resorption liberating
more TGF-P from the bone matrix (Zaidi et al., 2003; Fox & Lovibond, 2005; Casimiro
et al., 2009). TGF-P also acts on osteoblasts, reducing the availability of the osteoclast
differentiation factor, RANKL and thereby indirectly limits further osteoclast formation
(Fox & Lovibond, 2005).

1,3

The Vicious Cycle Hypothesis
Interaction between tumor cells and osteoclasts cause not only osteoclast

activation and subsequent bone loss, but also induce aggressive tumor cell proliferation.
Bone metastases are classified as osteolytic when a decrease in bone density occurs via
increased bone resorption (Mundy, 2002). Osteolysis results in increases in extracellular
Ca2+ and release o f bone-derived growth factors including TGF-P and insulin-like growth
factor 1 (IGF-1) (Casimiro et al., 2009). These growth factors bind to receptors on tumor
cells to promote proliferation and production of PTHrP, IL-8 and IL-11 (Mundy, 2002;
Casimiro et al., 2009).

Production o f PTHrP and IL-11 by tumor cells activates

osteoblasts to produce RANKL and downregulate OPG.

There is evidence that an

independent RANKL-mediated pathway is activated by IL-8 to stimulate osteoclast
development (Bendre et al., 2005). In this way a ‘vicious cycle’ is set up between the
tumor cells and bone (Fig. 1.3). In support of this mechanism, preventing osteoclast
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Metastatic bone cancer cells

Figure 1.3 Schematic representation o f the ‘vicious cycle’ between bone cells and tumour
cells in osteolytic métastasés. Tumour cells invade bone and release parathyroid hormonerelated protein (PTHrP) and interleukin-11 (IL-11) which stimulate osteoblast receptor
activator o f nuclear kB ligand (RANKL) expression which increases differentiation of
osteoclast precursors (OCP) and increases activity of mature osteoclasts. Resorbed bone
releases transforming growth factor 13 (TGF-13) and insulin-like growth factor 1 (IGF-1),
thereby stimulating tumour-cell proliferation and further PTHrP and IL-11 release, which, in
turn, causes more bone resorption (reviewed in Mundy, 2002).
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activation with current therapies such as bisphosphonates or blockade of RANKL
decreases both the osteolytic effects o f bone metastases and tumor growth (Mundy,
2002).

Blockade of tumor cell growth and osteoclast resorption by isoform-selective

PI3K inhibitors could be a useful therapeutic for bone metastasis.

1.4

Phosphatidylinositol-3 Kinase (PI3K)

1.4.1

PI3K Signaling Pathways
PI3K is an evolutionarily conserved signaling pathway. PI3K was first noted as a

key player in cancer research in the 1980s with the discovery of transforming activity of
viral oncogenes being functionally associated with PI3K activity (Whitman et al., 1985).
Further study went on to show PI3Ks phosphorylate the D3 hydroxyl position of the
inositol ring of phosphatidylinositides when stimulated by activated platelet-derived
growth factor receptors and certain oncogenes in the protein-tyrosine kinase family
(Kaplan et al., 1987; Auger et al., 1989; Varticovski et al., 1989). Through further study,
it was discovered that PI3Ks are heterodimers with separate regulatory and catalytic
subunits, and isoforms which can be grouped into three classes based on domain
organization, primary structure and substrate specificity (Vivanco & Sawyers, 2002;
Kong & Yamori, 2007; Bemdt et al., 2010).
Class I PI3Ks are the most studied and are clearly implicated in human cancers,
and will therefore be the focus o f our study. Class I PI3Ks are heterodimeric enzymes
consisting of a regulatory subunit in complex with a 110-kDa catalytic subunit which
phosphorylate phosphatidylinositols (Ptdlns) in the 3’ hydroxyl position.

Receptor

tyrosine kinases and G protein-coupled receptor signaling pathways activate PI3K, which
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Figure 1.4 Schematic representation of the Class IA and IB PI3K-Akt axis. Receptor tyrosine
kinases (RTK) and G protein-coupled receptor (GPCR) signaling pathways activate PI3K
(orange - catalytic subunit, red - regulatory subunit) which phosphorylâtes the primary
substrate phosphatidylinositol 4,5-bisphosphate (PIP 2) to phosphatidylinositol 3,4,5trisphosphate (PIP3). RTKs and GPCRs can also activate small GTPases such as Ras, which
then activate Class I PI3Ks (middle). Class IA PI3Ks include p 110 subunits a , P and 5 and are
activated by RTKs and associated binding proteins. Class IB PI3Ks include pi 10 subunit y
and P are activated by GPy proteins by GPCRs. Availability of P1P3 recruits
phosphatidylinositol-dependent kinase 1 (PDK1) and Akt to the membrane, where PDK1
phosphorylâtes Akt, which in turn activates many downstream effectors. Formation o f PIP3
also activates downstream effectors through other associated proteins. Schematic modified
from Vanhaesebroeck, et al. 2010.
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phosphorylates the primary substrate Ptdlns 4,5-bisphosphate (also called PIP2) to Ptdlns
3,4,5-trisphosphate (also called PIP 3). PIP 3 is mainly found on the plasma membrane,
although these lipids might also be present in endosomal compartments and even in the
nucleus (Vanhaesebroeck et al., 2010). PIP 3 induces downstream effects through adapter
proteins

such

as

protein

kinases

with

pleckstrin

homology

(PH)

domains

(phosphoinositide-dependent kinase-1 (PDK1), Akt, and Bruton’s tyrosine kinase
(BTK)), GTPase-activating proteins (GAP) for GTPases of the Rho, Ras and A rf families
(Vanhaesebroeck et al., 2005).

Notably, Akt is generally linked with PI3K activation

and phosphorylation o f both Thr308 and Ser473 are required for its full activation
(Vanhaesebroeck et al., 2005). Cellular responses to PI3K stimulation are diverse and
include, proliferation, cell cycle progression, migration and survival (Vivanco &
Sawyers, 2002; Kong & Yamori, 2007; Papakonstanti et al., 2008; Liao & Hung). Class
I PI3K includes the following catalytic p i 10 isoforms: a, P, y and 5. Class I PI3Ks are
further divided into class LA. and IB, due to differences in regulatory subunits and
activation (Vanhaesebroeck et al., 2005). Class IA includes isoforms p i 10 a, P and 8 and
regulatory subunits p85a, p85p, p55y (encoded by the same gene) and p55a, p55p, p50a
(alternative splice units of p85a) and signals downstream of receptor-tyrosine kinases
(Vivanco & Sawyers, 2002; Ward et al., 2003). In contrast, class IB includes catalytic
subunit pi lOy and regulatory subunit p i 01, and is activated by Py subunits downstream
o f G protein-coupled receptors (Vivanco & Sawyers, 2002). Also, recently pllO p has
been shown to be activated by GPy proteins by GPCRs (Guillermet-Guibert et al., 2008).
The class LA and IB PI3K-Akt pathway is summarized in Fig. 1.4.
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Attenuation o f Class I PI3K signaling pathways is achieved by dephosphorylation
o f the PI3K lipid products by a phosphatase known as phosphatase and tensin homolog
deleted on chromosome ten (PTEN) and Src homology 2-containing inositol-5phosphatase (SHIP). PTEN has both protein and lipid phosphatase activity. As a lipid
phosphatase, PTEN removes the 3’ phosphate of Ptdlns 3,4,5-trisphosphate to make
Ptdlns 4,5-bisphosphate. PTEN is considered a tumor suppressor. On the other hand,
SHIP phosphatases also act as negative regulators of PI3K activity, converting Ptdlns
3,4,5-trisphosphate to Ptdlns 3,5-bisphosphate.

There are two SHIP genes encoding

SHIP-1 and SHIP-2. SHIP-2 is widely expressed; conversely, SHIP-1 is exclusive to
hematopoietic cells including osteoclasts (Takeshita et a l, 2002; Rauh et a l, 2004; Zhou
et a l, 2006).
1.4.2

P13K p i 10 Isoform Function
The availability of two pharmacological pan-pllO PI3K inhibitors, wortmannin

(discovered and isolated from the fungi Pénicillium wortmanni) and LY294002
(reversible, morpholino derivative o f the quercetin flavonoid; structurally unrelated to
wortmannin) have contributed greatly to our understanding o f the biological roles of
PI3K and their effector proteins (Ward et a l, 2003; Maira et a l, 2009).

Although,

wortmannin and LY294002 have been shown to have therapeutic potential, such as
decreased cancer growth in vitro and in vivo, both compounds are toxic and show severe
side effects (Cheng et a l, 2005; Liu et a l, 2009; Maira et a l, 2009; Teranishi et a l,
2009).

Neither wortmannin nor LY294002 exhibits any degree o f selectivity for

individual p i 10 isoforms (Engelman, 2009).

PI3K inhibitors work by binding to the

ATP-binding site on class I PI3Ks (Liu et a l, 2009). Massive efforts have been put forth
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by academic and private laboratories to develop isoform-selective PI3K inhibitors as
therapeutics.

Huge advances have been made by crystallography of PI3Ks and their

chemical scaffolds.

Three dimensional structures o f isoforms have been crucial in

structure-based drug design approaches to identify new molecular entities to improve
specificity and potency (Maira et al., 2009) and therefore, decrease potential side effects.
There is growing evidence for distinct biological roles o f specific PI3K isoforms.
Research using gene knockouts in mice, as well as new pharmacological inhibitors have
started to address the issues on PI3K isoform overlap and non-redundant functions, and
have revealed important roles for specific PI3K isoforms in immunity, metabolism and
cardiac function.

Distinct roles o f PI3K isoforms in different cell types could be

explained by their relative expression levels. For example, MDA-MB-231 breast cancer
cells express low levels of p i 10 a and high levels of p i 105 which influence stimulusinduced cytoskeleton changes (Sawyer et al., 2003). Consistent with this hypothesis,
endothelial cells express low levels o f p i 105 and moderate levels o f p i 10a to regulate
cell migration (Graupera et al., 2008; Papakonstanti et al., 2008). Generally, p i 10a and
p i 1Op are found to be ubiquitously expressed, whereas p i 105 expression is low in most
cells, but highly enriched in hematopoietic stem cells (Papakonstanti et al., 2008). In
knock out studies o f p 110 a, it was determined that homozygous mutations led to
embryonic lethality; whereas mice bearing heterozygous mutations were viable, but
displayed defective responsiveness to hormones such as, insulin and leptin that led to
reduced somatic growth, hyperinsulinaemia, glucose intolerance, hyperphagia and
increased adiposity (Knight et al., 2006; Papakonstanti et al., 2008; Kim et al., 2009).
Further, important links have been made between p l i o p and cell survival in thrombosis
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and prostate tumor growth (Bradley et al., 2008; Jia et al., 2008); pi 108 and the
inflammatory response (proliferation and function of B cells and T cells); and p i lOy and
fibroblast and B cell differentiation and proliferation (Graupera et al., 2008; BeerHammer et al., 2010). However, at present, there is little evidence about the functions of
PI3K isoforms in osteoclasts (summarized below).
1.4.3

The Role of PI3K in Cancer
The PI3K pathway is one o f the most commonly activated signaling pathways in

human cancer and it has been estimated that at least 50% of all cancer types are related to
deregulation o f this signaling pathway (Jia et al., 2008; Falasca, 2011). Activation of this
pathway can be brought about in various ways that include, a) activating point mutations
in the p i 10a isoform or over expression o f non-mutated p i 10 a, P, y and 5 isoforms
(Knight et al., 2006; Jia et al., 2008), b) activated Ras oncogenes that allosterically
stimulate PI3K p i 10 isoforms (Kang et al., 2006), c) loss o f expression of PTEN, a
phosphatase responsible for negative regulation o f PIP3 formation (Vivanco & Sawyers,
2002; Knight et al., 2006), or d) overexpression or constitutive activation o f oncogenic
receptor tyrosine kinases (Lurje & Lenz, 2009).
1.4.4

The Role of PI3K in Bone
PI3K has been shown to be a critical downstream player in osteoclasts, mediating

its effects through at least three cell-surface receptors: M-CSF-activated c-fms, RANKLactivated RANK, and the extracellular matrix receptor avP3. Wortmannin in osteoclasts,
disrupts actin ring formation, ruffled border formation, chemotaxis and reduces pit
formation during resorption (Hall et al., 1995; Nakamura et al., 1995; Pilkington et al.,
1998). The effector actions o f PI3K in osteoclasts are diverse, influencing survival and
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activity, mediating cytoskeletal remodeling and motility, and regulating attachment
structures.

Less is known about the roles o f PI3K in osteoblasts, however evidence

suggests a role for PI3K in osteoblast differentiation and survival (Golden & Insogna,
2004).
1.4.5

PI3K pi 10 Isoforms in Osteoclasts
A recent study by Kang and colleagues reports that the PI3K catalytic isoform

pllOy plays an important role in bone homeostasis (Kang et al., 2010). They report that
genetic inactivation o f the pllO y gene leads to an increase in bone mass, likely due to
impairment in osteoclastogenesis. Decreased osteoclast formation was accompanied by
downregulated osteoclast gene expression, including such genes as osteoclast-associated
immunoglobulin-like receptor (OSCAR), DC-STAMP, and NFATcl. PI3K pllOy is
activated by Py subunits downstream o f GPCRs (Vivanco & Sawyers, 2002).

For

example, lysophosphatidic acid (LPA) activates GPCRs in osteoclasts to increase
survival (Lapierre et al., 2010). Interestingly, pllOy deficiency impaired M-CSF-induced
Akt phosphorylation and therefore, the authors concluded that p i lOy is likely to mediate
its effects on osteoclastogenesis through chemokine receptor signaling which cooperates
with M-CSF-induced signaling pathway.

They suggest that GPCR-mediated PI3K

activation (likely through chemokine receptors) provides a biologically significant
supplementation to the M-CSF-mediated protection from apoptosis (Kang et al., 2010).
There is also evidence for a role o f p i 10a in bone provided by Grey and
colleagues. In their study, they assessed the effects o f pharmacological inhibitors on pi 10
a , P and 5 in the RAW 264.7 monocyte-macrophage-like cell line. They determined that
the isoform-selective inhibitor PIK75 (pi 10a inhibitor) decreased resorptive activity by
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osteoclast-like cells and concentration-dependently decreased osteoclastogenesis from
undifferentiated RAW 264.7 cells, with no effect o f pi 1Op and 8 inhibitors (Grey et al.,
2010). Thus further investigation into the roles of PI3K isoforms is required.
1.4.5.1 PI3K Activation by M-CSF
M-CSF is a growth factor that binds to its tyrosine kinase receptor, c-fms which
activates PI3K to promote proliferation, motility and survival (Varticovski et al., 1989).
PI3K is a known partner with cytoplasmic tyrosine kinase c-src and Ras in mediating the
effects o f activated c-fms (Grey et al., 2000; Fukuda et al., 2005; Sakai et al., 2006).
Notably, osteoclasts express the highest concentration of c-fms receptor of any cell type
in the hematopoietic cell linage (Varticovski et al., 1989). A growing body of evidence
shows that PI3K plays an integral role in mediation of M-SCF-induced pseudopod
ruffling and motility in osteoclasts (Pilkington et al., 1998; Palacio & Felix, 2001;
Fukuda et al., 2005). Antibody blockade o f PI3K pi 10 subunit isoforms in macrophages
has revealed distinct downstream responses to M-CSF that are mediated by specific PI3K
isoforms (Vanhaesebroeck et al., 1999).

In particular, p i 1Op and p i 108 isoforms are

required for c-fms-mediated cell migration and cytoskeletal reorganization, while the
p i 10a isoform has a role in c-fms-mediated DNA synthesis (Vanhaesebroeck et al.,
1999).
1.4.5.2 PI3K Activation by RANKL
Evidence indicates an important role for PI3K downstream from activated RANK,
in which c-src acts as a mediator connecting RANK to PI3K/Akt signaling in osteoclasts
(Wada et al., 2006).

When the expression of c-src is suppressed, the number of

multinucleated cells formed is significantly reduced in vitro (Kumagai et al., 2004).
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Also, Sugatani and colleagues have shown that PTEN overexpression in RAW 264.7
osteoclast precursors blocks RANKL-induced osteoclast differentiation, as well as Akt
activation (Sugatani et al., 2003). This suggests that PI3K is an important participant in
RANK-mediated

differentiation.

In

parallel,

the

importance

osteoclastogenesis has been shown in vitro and in vivo.

of

SHIP1

in

In vitro cultures showed

increased osteoclastogenesis and increased numbers o f hyper-resorptive osteoclasts in
SHIP 1-deficient cells as a result o f hypersensitivity to stimulation with RANKL and MCSF (Takeshita et al., 2002).

Particularly, SHIP1 deficient mice have osteoporosis

(Takeshita et al., 2 0 0 2 ).
The activation and fusion o f osteoclasts require the adaptor molecule DNAXactivating protein of 12 kDa (DAP 12), which contains immunoreceptor tyrosine-based
activation motifs (ITAM).

The receptor, known as triggering receptor expressed on

myeloid cells-2 (TREM2), is the main DAP12-associated receptor in osteoclasts. In vitro
experiments have shown that deficiency in DAP 12 or TREM2 leads to impaired
osteoclast development and the formation of mononuclear osteoclasts. It has been shown
that this complex is downstream o f RANK, converging on PI3K (Peng et al., 2010).
1.4.5.3 PI3K Activation by integrins
Osteoclasts adhere to the bone surface via av(33 integrins, which engage the
organization o f dynamic attachment structures.

These multi-molecular structures are

called podosomes, comprised o f actin, vinculin, gelsolin, a-actinin, talin, and other
scaffolding molecules (Golden & Insogna, 2004; Teitelbaum, 2007; Novack &
Teitelbaum, 2008). PI3K has been shown to be coimmunoprecipitated with avP3 integrin
from osteoclasts (Lakkakorpi et al., 1997). Interaction o f gelsolin and c-src with PI3K
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occurs directly through the SH2 domains on the p85 subunit of PI3K (Chellaiah &
Hruska, 1996; Chellaiah et al., 1998; Grey et al., 2000). Association of the actin-binding
protein gelsolin with PI3K is essential for actin filament formation in osteoclasts.
Gelsolin-deficient osteoclasts are hypomotile and fail to produce podosomes (Chellaiah et
al., 1998).

c-src and PI3K function at the point where adhesion signals converge,

transmitting the signals for proper actin cytoskeletal organization that is required for
resorption activity.

1.5

Rationale, Objectives and Hypothesis of Research

1.5.1

Rationale
Currently, investigators have begun to elucidate effects of isoform-selective PI3K

inhibitors on varying cell types. Some inhibitors have shown considerable promise for
the treatment of cancer and are making their way into the early phases o f clinical trials
(Lannutti et al., 2011). There is evidence that the PI3K pathway affects a number of
osteoclast

functions,

including

differentiation

(Mandal

et al.,

2009),

survival

(Munugalavadla et al., 2008), chemotaxis (Pilkington et al., 1998, 2001), cytoskeletal
organization (Lakkakorpi et al., 1997) and bone resorption (Nakamura et al., 1995;
Nakamura et al., 1997; Palacio & Felix, 2001; Fukuda et al., 2005). Generally, PI3K
p i 10a and pllOp are ubiquitously expressed, whereas p i 105 expression is low in most
cells, but highly enriched in cells of the hematopoietic lineage (Papakonstanti et al.,
2008). In macrophages, DNA synthesis is inhibited by antibodies to p i 10a specifically,
whereas actin reorganization and migration are inhibited by antibodies against pl lOp and
pi 105, specifically (Vanhaesebroeck et al., 1999). These findings support the hypothesis
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that specific PI3K isoforms have distinct signaling roles. In osteoclasts, it is unknown
whether the isoforms are functionally redundant or have distinct roles.

There is

possibility that isoform-selective PI3K inhibitors can serve not only as therapeutics for
bone diseases, but also as a tool for identifying roles o f different PI3K isoforms in
osteoclasts.

Currently, little is known about the effects of isoform-selective PI3K

inhibitors on osteoclasts.
1.5.2

Objectives
We are focusing on the PI3K Class I p i 10 isoforms a , p, y and 6 , with the goal of

identifying inhibitors useful for suppressing osteoclast function.
1. To characterize the effects o f isoform-selective PI3K inhibitors on the viability
o f monocyte-macrophage-like cells.
2. To investigate the effects of isoform-selective PI3K inhibitors on osteoclast
morphology and motility.
3. To determine the effect o f isoform-selective PI3K inhibitors on cytoskeletal
organization in osteoclasts plated on varying substrata.
4. To evaluate the effect o f isoform-selective PI3K inhibitors on osteoclast
survival.
1.5.3

Hypothesis

It is hypothesized that a PI3K isoform will be identified that selectively alters
osteoclast cytoskeletal function and survival.
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CHAPTER TWO

Effects of isoform-selective phosphatidylinositol-3 kinase inhibitors on
osteoclasts: Actions on cytoskeletal organization and survival
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2.1

Chapter Summary
Phosphatidylinositol

3-kinases

(PI3K)

participate

in

numerous

signaling

pathways, and control a number o f distinct biological functions. Studies using pan-PI3K
inhibitors suggest roles for PI3K in osteoclasts, but little is known about the function of
specific PI3K p i 10 isoforms in these cells. Our objective was to determine effects of
isoform-selective PI3K inhibitors on osteoclasts. The following inhibitors were
investigated (targets in parentheses): wortmannin and LY294002 (pan-pllO), PIK75 (a),
GDC0941 (a, 8 ), TGX221 (p), AS252424 (y) and IC87114 (6 ). In addition, we
characterized the novel PI3K inhibitor CAL-120 and found it was highly selective for
PI3K8. Only high concentrations o f PIK75 and LY294002 reduced the viability of
monocyte-macrophage-like cells. Osteoclasts were isolated from the long bones of
neonatal rats and rabbits. Wortmannin, GDC0941, IC87114 and CAL-120 induced
dramatic retraction of osteoclasts within 15-20 min to 65-75% o f initial area. In contrast,
there was no significant retraction in response to vehicle, PIK75, TGX221 or AS252424.
Moreover, wortmannin and CAL-120, but not PIK75 or TGX221, disrupted filamentous
F-actin belts; and CAL-120 inhibited the formation of sealing zones in osteoclasts on
resorbable substrates. In contrast to their selective actions on cytoskeletal organization,
PIK75, TGX221 and CAL-120 blocked the stimulatory effects o f RANKL on osteoclast
survival. These data are consistent with a specific role for PI3K8 in regulating the
osteoclast cytoskeleton. In contrast, multiple PI3K isoforms contribute to the control of
osteoclast survival. Thus, the PI3K5 isoform, which has more limited tissue distribution
than PI3Ka and PI3K(3, is an attractive target for novel anti-resorptive therapeutics.
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2.2

Introduction
Bone is remodeled by the coupled process o f breakdown of old bone by

osteoclasts and formation of new bone by osteoblasts (Novack & Teitelbaum, 2008).
Maintenance o f bone integrity is dependent on the coordinated activity of osteoclasts and
osteoblasts, with perturbations to this balance causing skeletal disease (Manolagas,
2000). Osteoclasts and osteoclast precursors receive signals from adjacent cells, soluble
mediators and the extracellular matrix to regulate changes in differentiation, survival,
resorptive activity and recruitment to bone (Teitelbaum, 2007).
Class I phosphatidylinositol-3 kinases (PI3K) have critical roles in a variety of
cellular processes such as metabolism, differentiation, survival and migration (Vivanco &
Sawyers, 2002). PI3Ks are further divided into class IA and IB, all o f which are
heterodimeric enzymes consisting o f a regulatory subunit in complex with a HOkDa
catalytic subunit that phosphorylâtes the primary substrate phosphatidylinositol 4,5bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) (Vanhaesebroeck
et a l, 2005). PIP 3 is the active form, and mediates downstream effects through adapter
proteins such as protein kinases with pleckstrin homology domains and GTPaseactivating proteins (Vivanco & Sawyers, 2002; Liu et a l, 2009). Class IA includes
catalytic isoforms pi 10 a (PI3Ka), P (PI3KP), and ô (PI3K6) and regulatory subunits
p85a or p, p55a or y, p50a and signals downstream of tyrosine-receptor kinases (TRK).
In contrast, Class IB includes catalytic subunit pllOy (PI3Ky) and regulatory subunits
p i 01 and p84, and signals downstream o f G protein-coupled receptors (GPCR) (Vivanco
& Sawyers, 2002; Vanhaesebroeck et a l, 2005). Recent data indicate that most class I
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PI3K subunits might be activated directly (e.g. G[3y protein activating PI3Ky and PI3KJ3
(Guillermet-Guibert et al., 2008)) or indirectly (e.g. Ras) (Vanhaesebroeck et al., 2010).
Genetic manipulation experiments, as well as utilizing new pharmacological
inhibitors have allowed researchers to address issues on PI3K isoform overlap and nonredundant functions, and have revealed important roles for specific PI3K isoforms in
immunity, metabolism and cardiac function. Some examples include, PI3Ka in insulin
signaling and oncogenesis, PI3KP in thrombosis, and PI3K5 and PI3Ky in immune
function and inflammation (Vanhaesebroeck et al., 2005; Engelman, 2009; Liu et al.,
2009). Generally, PI3Ka and PI3KP are thought to be ubiquitously expressed, whereas
PI3K5 and PI3Ky expression is low in most cells, but high in cells of hematopoietic
origin (Chantry et al., 1997; Kok et al., 2009). Recently developed isoform-selective
PI3K inhibitors show promise for the treatment o f inflammatory disease (Marone et al.,
2008; Durand et al., 2009) and cancer (Cleary & Shapiro, 2010), and are making their
way into the early phases o f clinical trials (Liu et al., 2009; Lannutti et al., 2011).
In osteoclasts PI3K affects survival, resorptive activity, cytoskeletal organization
and motility (Hall et al., 1995; Pilkington et al., 1998, Nakamura, 1995; Golden &
Insogna, 2004; Chellaiah, 2006). Investigations on PI3K isoforms in macrophages
demonstrate that PI3K8 is important in cell migration and vesicle trafficking
(Papakonstanti et al., 2008; Low et al., 2010). In addition, investigations in osteoclasts
demonstrate that PI3Ky modulates osteoclastogenesis (Kang et al., 2010). Despite our
current understanding, relatively little evidence is available on the functions of PI3K
isoforms in osteoclasts, thereby providing a rationale for ongoing evaluation and possible
therapeutic development.
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2.3

Materials and Methods

2.3.1

Materials
Medium 199 (M l99, Earles, 12340) buffered with 25 mM HEPES and 26 mM

HCO 3', HCO 3" -free M l 99 (Hanks, 12350) buffered with 25mM HEPES, heat-inactivated
fetal bovine serum (FBS, 12483), and antibiotic solution (penicillin 10,000 units/ml;
streptomycin 10,000 pg/ml; and amphotericin B 25 pg/ml, 15240) were purchased from
Invitrogen (Burlington, Canada). Dulbecco’s modified Eagles medium (DMEM, D7777)
with 4500 mg/L glucose, L-glutamine, and sodium pyruvate, without sodium bicarbonate
were purchased from Sigma-Aldrich (St. Louis, MO). Bovine serum albumin (BSA)
(crystallized) was from ICN Biomedicals. Mounting medium (Vecta-Shield) was from
Vector Laboratories (Burlingame, CA,). Recombinant Mouse RANKL was purchased
from R&D systems (Minneapolis, MN). GDC0941 bismesylate (1377), TGX221 (1417),
AS252424 (1424) and PIK75 (1334) were purchased from Axon Med Chem (Groningen,
Holland). IC87114 and CAL-120 were kind gifts from Gilead Sciences (Forest City, CA).
Wortmannin (681675) and LY292004 (440202) were purchased from Calbiochem
(Darmstadt, Germany). Stock solutions o f PI3K inhibitors were prepared in dimethyl
sulfoxide (DMSO) from Sigma-Aldrich. Vehicle controls were DMSO in all cases.
2.3.2

Osteoclast Isolation

Osteoclasts were isolated from the long bones of newborn Wistar rats or New
Zealand White rabbits, as described in previous publications (Naemsch et al., 2001;
Pereverzev et al., 2008). All procedures were approved by Council on Animal Care of
The University o f Western Ontario and were in accordance with the guidelines of the
Canadian Council on Animal Care. Briefly, long bones are dissected free of soft tissue
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and minced with a scalpel in HCO 3' buffered M l 99 supplemented with 15% FBS and 1%
antibiotic solution. The resulting cells are suspended by repeated passage through a glass
pipette and plated on FBS-coated 12-mm glass cover slips, MatTek glass bottom culture
dishes (MatTek Corporation, Ashland, MA), or calcium phosphate-coated discs (BD
BioCoat™ Osteologic™ Discs, BD Biosciences, Bedford, MA). Freshly isolated
osteoclasts were incubated at 37°C in 5% CO 2 for 1 h, washed gently with PBS to
remove non-adherent cells and incubated in medium. Osteoclasts are identified as having
three or more nuclei, positive staining for tartrate-resistant phosphatase (TRAP),
retracting in response to calcitonin, and the ability to resorb mineralized substrates.
2.3.3

I n v itr o

Kinase Profiling

Biochemical in vitro lipid kinase assays were analyzed using the SelectScreen®
biochemical kinase assay service (Invitrogen Ltd.). A stock solution o f CAL-120 was
prepared in DMSO at a concentration o f 10 mM. Ten-point kinase inhibitory activities
were measured over a concentration range (5 nM to 104 nM) with ATP at a concentration
consistent with each enzyme’s Km.
2.3.4

PI3K Isoform-Selective Cell-Based Assays
Murine embryonic fibroblast (MEFs, American Type Culture Collection (ATCC),

Manassas, VA) were used for the analysis o f PI3K a and PI3K0 signaling. Cells were
transferred to serum-free medium for two hours and then stimulated with platelet-derived
growth factor (PDGF) (10 ng/mL; Cell Signaling, Danvers, MA) or LPA (10 pM;
Echelon, Salt Lake City, UT) for 10 min at 37°C to activate PI3Ka and PI3KJ3,
respectively. After washing once in cold phosphate-buffered saline (PBS), the cell pellet
was resuspended in lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol,
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1% Triton X-100, 1.5 mM MgC^, 1 mM ethylene glycol tetraacetic acid (EGTA), 100
mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM NaV 0 4 , 1 pg/mL leupeptin, and 1
pg/mL aprotinin) for 15 minutes on ice. Whole-cell lysates were obtained by
centrifugation at 14000g for 15 minutes at 4°C, and the soluble protein was analyzed by
Western blotting for Akt and pAkt levels.
For the analysis o f PI3K5 and PI3Ky signaling, basophil activation was measured
in isolated peripheral blood mononuclear cells (PBMC) or whole blood. Blood samples
were obtained after written informed consent obtained in accordance with the Declaration
o f Helsinki and with local institutionally approved protocols. Basophil activation was
measured using the Flow2 CAST kit according to the manufacturer's standardized
methods (Buhlman Laboratories AG, Switzerland). Briefly, PI3K5 was activated with
anti-FceRI and PI3Ky was activated with formyl-methionyl-leucyl-phenylalanine (fMLP)
in the absence or presence of increasing concentrations of CAL-120. To monitor the
basophil cell population and cellular activation, anti-CD63-FITC and anti-CCR3-PE
antibodies were added to each sample. Cells were fixed and analyzed on a FC500MPL
flow cytometer.
2.3.5

Assessment of Cell Viability
The virally transformed murine monocyte-macrophage-like cell line RAW 264.7

was obtained from the ATCC (Manassas, VA). The effect of inhibitors on RAW 264.7
cell survival was evaluated using the methylthiazoltetrazolium (MTT) assay. RAW 264.7
cells were seeded in Falcon flat bottom 96-well plates (353072) at a density o f 2.5 - 3 x
104 cells/cm 2 in 100 pL DMEM medium with 10% FBS and 1% anitbiotic. After seeding,
the cells were allowed to attach for 24 h then exposed to control or treatment for 24 h at
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varying concentrations. After incubation at 37°C in 5% CO 2, MTT substrate (Roche
Applied Science, Mississauga, ON) was added at a final concentration of 0.5 mg/mL for
4 h. Following 4 h incubation, 100 pL solubilization solution was added to each well to
dissolve the formazan crystals and samples were analyzed after 24 h overnight.
Spectrophotometrical absorbance o f the samples were taken using an ELISA reader by
Tecan (Mannedorf, Switzerland) using a wavelength o f 550 nm and a reference wave
length of 700 nm.
2.3.6

Assessment of Osteoclast Morphology
To perform time-lapse recordings culture medium was removed and replaced with

a HEPES-buffered M l 99 medium (HCOs'-free) supplemented with 15% FBS and 1%
antibiotic solution. Dishes were placed in a heated stage and maintained at ~35°C.
Osteoclasts were observed using a Nikon Eclipse TE300 phase contrast microscope and
images were captured using Image Master 5 Software (Photon Technology International).
For data analysis, the periphery o f each osteoclast was traced periodically to quantify the
planar area using Image Master Software. Planar area is expressed as a percentage of the
average initial area before time 0. Initial planar area was 5440 ± 3200 pm (mean ± S.D.,
n - 90 osteoclasts).
2.3.7

Assessment of Osteoclast F-actin Organization
Osteoclasts were plated on FBS-coated glass cover slips or BD BioCoat™

Osteologic1M cover slips and fixed with 4% paraformaldehyde with 2% sucrose in PBS
for 10 min at room temperature, washed three times with PBS, and permeabilized with
0.1% Triton X-100 in PBS for 10 min at room temperature. Following three washes with
PBS, cells were incubated in 1% - 3% bovine serum albumin for 1 h at room temperature,
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stained for filamentous actin (F-actin) using 6 6 nM Alexa Fluor 488 phalloidin for 20
min at room temperature in the dark, and washed three times with PBS. Following the
wash, osteoclasts were visualized for fluorescence. The number of osteoclasts portraying
a complete F-actin belt or sealing zone present under each condition were counted along
with to the total number o f osteoclasts (per 12 mm coverslip). Osteoclasts observed to
have a F-actin belt or sealing zone to encompass 75% or more o f the cell perimeter were
counted as ‘complete,’ and anything below 75% was counted as ‘incomplete’. Images
under each condition were captured with Zeiss AxioVision 4.8 imaging software using a
Zeiss Observer Z1 microscope (Chester, VA) or Zeiss LSM 5.0 software using a Zeiss
LSM 510 META confocal microscope.
2.3.8

Assessment of Osteoclast Survival
Rat osteoclasts were isolated and plated on FBS coated coverslips and incubated

at 37°C in 5% CO 2 for 1 h. Coverslips were then washed gently with PBS to remove non
adherent cells and incubated for an additional 0.5-1 h in HCCV-buffered M l 99
supplemented with 15% FBS and 1% antibiotic solution. Osteoclasts were then counted
using phase-contrast microscopy as described previously (Korcok et al., 2005). Cultures
were incubated for an additional 15-18 h at 37°C in 5% CO2. Following incubation, the
number of osteoclasts per coverslips was counted, and survival was expressed as the
percentage o f the initial osteoclast number on the same coverslip. Number of osteoclasts
per coverslip was 75 ± 25 (mean ± S.D., n — 90 coverslips).
2.3.9

Statistical Analysis

Results are presented as means ± S.E.M. Differences between two groups were
evaluated using a Student’s t-test and differences among two or more groups were
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evaluated by one-way analysis o f variance (ANOVA) followed by Tukey’s multiple
comparisons test or two-way ANOVA followed by Bonferroni’s multiple comparisons
test, respectively. Differences were accepted as statistically significant at p < 0.05.

2.4

Results

2.4.1

CAL-120 is a Potent and Selective Inhibitor of PI3K8
CAL-120

((S)-2-( 1-(9H-purin-6-ylamino)ethyl)-6-fluoro-3 -phenylquinazolin-

4(3H)-one) was characterized using in vitro and cell-based kinase assays. Other
compounds used in the study were characterized in previous studies (i.e. PIK75 (Knight
et al., 2006), TGX221 (Jackson et al., 2005), AS252424 (Pomel et al., 2006), IC87114
(Sadhu et al., 2003), GDC0941 (Folkes et al., 2008), Wortmannin and LY294002
(Marone et al., 2008)). We demonstrate that CAL-120 was 25- to 300-fold more selective
for PI3K5 relative to other PI3K class I enzymes (IC50: PI3Ka 357 nM; PI3K0 153 nM;
and PI3Ky 47 nM; PI3K5 0.8 nM). CAL-120 was also 103-fold more selective against
PI3K8 than against related kinases, such as Clip, hVPS34, DNAPK, and mTOR. No
other activity was observed against a panel of >340 diverse kinases (Table 2.1 A).
EC 50 values were determined using in vitro cell-based assays as described
previously (Lannutti et al., 2011). In fibroblasts, the PDGF receptor signals through
PI3Ka and the G protein-coupled receptor for LPA signals through PI3KP (Jia et al.,
2008). CAL-120 reduced PDGF-induced pAkt by only 25% at 10 pM, whereas CAL-120
reduced LPA-induced pAkt by 50% at 1.2 pM (Table 2 .IB). Expression of PI3Ky and
PI3K8 is largely restricted to cells o f hematopoietic origin, including basophils. In
basophils, FcsRI signals through PI3K8, whereas fMLP signals through PI3Ky via G
protein-
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A
Class II Class III
Related kinases
PI3K PI3K
p110a p110p p110y p1105 Clip hVPS34 PIP5Ka PIP5KP DNAPK mTOR
Class 1PI3KS

357

153

47

0.8

>103

>103

>103

>103 >103

>103

*AII values shown are IC50values (nM).

B
PI3K
Isoforms
Cell
Type
Stimulus

PI3Ka
Primary
Fibroblast
PDGF-induced
pAkt

PI3Kp
Primary
Fibroblast
LPA-induced
pAkt

EC50(nM)

>20,000

1,200

PI3Ky
Primary
Basophil
fMLP receptor
CD63
expression
2,345

PI3KÔ
Primary
Basophil
Anti-FcsRIinduced CD63
expression
4.9

*ln serum-containing medium, values show 2-fold increase
Table 2.1. CAL-120 is a potent and selective inhibitor o f PI3K8. A, CAL-120 in vitro
activity profiles (IC S0 values) against recombinant enzymes o f PI3K Class I, II, and III and
other related kinases. CAL-120 was dissolved in dimethyl sulfoxide at a stock concentration
o f 10 mM and 10-point kinase inhibitory activities were measured with ATP at a
concentration consistent with the Kmo f each enzyme. B, Potency of CAL-120 in cell-based
assays evaluating the activity o f specific PI3K Class I isoforms (EC S0 values). For the
analysis of PI3Ka and PI3KP signaling, murine embryonic fibroblasts were incubated for 1
h with several concentrations o f CAL-120 followed by stimulation with PDGF or LPA.
Soluble protein was analyzed by Western blotting for Akt and pAkt473 levels. For the analysis
o f PI3Ky and PI3K5 signaling, basophil activation was measured in isolated peripheral
blood mononuclear cell or whole blood. PI3Ky was activated with formyl-methionylIeucyl-phenylalanine and PI3K8 was activated with anti-FCsRI. To determine the basophil
cell population and to monitor cellular activation, anti-CCR3-PE and anti-CD63-FITC
antibodies were added and each sample was analyzed on a FC500MPL flow cytometer,
respectively. In vitro kinase studies n = 4 independent experiments and for isoformselective cell-based assays n = 8 independent experiments. Experiments were carried out at
Calistoga Pharmaceutical in Seattle, Washington by Dr. B. Lannutti and A. Kashishian.
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coupled receptors with either stimulus leading to expression of CD63 (Laffargue et al.,
2002; Ali et al., 2004). CAL-120 suppressed FcsRI PI3K5-mediated CD63 expression
with an EC 50 o f 4.9 nM, and fMLP PBKy-mediated CD63 expression with an EC 50 of
2345 pM (Figure IB). Thus, CAL-120 had 240- to 4000-fold selectivity for PI3K6 over
the other class I PI3K isoforms and virtually no effect on other kinases.
2.4.2

Effect of Isoform-Selective PI3K Inhibitors on the Viability of MonocyteMacrophage-like Cells

RAW 264.7 cells are a leukemic murine monocyte/macrophage cell line that,
when treated with RANKL (100 ng/ml) for 4 days, produce multinucleated, TRAPpositive osteoclast-like cells (Armstrong et al., 2009). To assess possible toxicity, we
incubated RAW 264.7 cells with inhibitors at varying concentrations for 24 h, after which
viability was assessed using an MTT assay. We compared control cultures to those in the
presence o f isoform-selective PI3K inhibitors. The inhibitors were: wortmannin (panp i 10), LY294002 (pan-pl 10), GDC0941 (a, p and 6 inhibitor), PIK75 (a), TGX221 (P),
AS252424 (y), IC87114 (8) and CAL-120 (8). Toxic effects were only observed for
PIK75, at concentrations of 1 and 10 pM, and LY294002, at concentration of 100 pM (p
< 0.05) (Fig. 2.1). Since toxic effects were observed only for PIK75 and LY294002 at
high concentrations it was concluded that lower concentrations with all PI3K inhibitors
were not effecting the cell viability.
2.4.3

Inhibition of PI3K8 Induces Osteoclast Retraction
Conventional PI3K inhibitors such wortmannin and LY294002 have been shown

to induce osteoclast retraction and inhibit motility (Pilkington et al., 1998). However,
these conventional inhibitors are not selective for particular PI3K pi 10 isoforms,
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Fig. 2.1. Effects o f PI3K isoform-selective inhibitors on viability o f RAW 264.7 monocytemacrophage-like cells. RAW-264.7 cells were treated with inhibitors (100 pM to 10 pM, or
1 nM to 100 pM for LY294002) or vehicle for 24 h, after which viability was assessed using
an MTT assay. Data are expressed as a percentage o f values for vehicle-treated control
samples. Dashed lines indicate 100%. Viability was diminished only by PIK75 at
concentrations o f 1 and 10 pM and LY294002 at 100 pM. Data are means ± S.E.M., n = 4
independent experiments, except for IC87114 and LY294002 where n = 3. Differences were
assessed using one-way ANOVA and Tukey's multiple comparisons test. * indicatesp < 0.05
compared to vehicle.
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Fig. 2.2. Wortmannin and CAL-120 induce osteoclast retraction. Rat osteoclasts were
bathed in HEPES-buffered M l 19 medium with 15% FBS and antibiotics and imaged using
time-lapse phase-contrast microscopy. A-E illustrates 5 different osteoclasts, each
illustrated at 3 times. Images labeled time 0 min illustrate the cells immediately prior to
addition o f vehicle, wortmannin (1 pM), PIK75 (1 pM), TGX221 (1 pM), or CAL-120 (1
pM) to the bath. Prior to treatment, osteoclast lamellipodia were well spread and motile.
Wortmannin and CAL-120 induced prompt retraction o f lamellipodia, which was sustained
for at least 30 min. Images are representative o f the responses of 9-15 osteoclasts from 4-8
independent preparations. Scale bar represents 30 pm for all panels. Images displayed were
gamma adjusted for clarity o f the periphery. Supplemental Videos 1 and 2 illustrate the
responses o f cells in panels A and E, respectively.
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Fig. 2.3. PI3K8 is important in osteoclast lamellipodia spreading. Rat osteoclasts were
imaged by time-lapse phase-contrast microscopy and treated with the indicated test
substance at time 0, as described in the legend to Fig. 3. Image analysis software was used to
calculate the planar area o f osteoclasts at 4-min intervals. Data are expressed as a percentage
o f the mean initial area before time 0 (from -24 to 0 min) and are means ± S.E.M. A, There
was no marked change in osteoclast area in vehicle-treated cells (n - 4 independent
preparations, a total of 9 osteoclasts). B-D, The following inhibitors had no net effect on
osteoclast area: TGX221 (1 pM, n - 8 independent preparations, a total o f 10 osteoclasts),
PIK75 (1 pM, n = 5 independent preparations, a total o f 10 osteoclasts), and As252424 (1
pM, n = 5 independent preparations, a total o f 9 osteoclasts). E-I, In contrast, the following
inhibitors caused significant, sustained decreases in osteoclast planar area: CAL-120(1 pM,
n - 5 independent preparations, a total of 15 osteoclasts), wortmannin (1 pM, n - 4
independent preparations, a total o f 8 osteoclasts), GDC0941 (1 pM, n = 5 independent
preparations, a total o f 8 osteoclasts), LY294002 (50 pM, n = 3 independent preparations, a
total of 7 osteoclasts) and IC87114 (5 pM, n = 4 independent preparations, a total of 12
osteoclasts). Differences were assessed using a two-way ANOVA and Bonferroni's multiple
comparisons test. * indicatesp < 0.05 compared to vehicle at the corresponding times.
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Fig. 2.4. Reversibility of the effects o f the PI3K5-selective inhibitor CAL-120 on osteoclast
retraction. Rat osteoclasts were imaged by time-lapse phase-contrast microscopy and
exposed to vehicle or CAL 120 (1 pM) from 0 to 30 min, as indicated by the horizontal bar
above the data in B. A illustrates 2 different osteoclasts, each shown at 3 times. Ai,
lamellipodia remain well spread in vehicle-treated osteoclast. Aii, CAL-120 induces
retraction o f lamellipodia (evident at 15 min). Following wash out o f CAL-120 at 30 min,
lamellipodia respread (evident at 40 min). B, Planar area o f osteoclasts was calculated
periodically and expressed as a percentage o f the mean initial area before time 0 (from -10 to
0 min). Data are means ± S.E.M. There was no marked change in osteoclast area in vehicletreated cells (n = 3 independent preparations, a total of 8 osteoclasts). In contrast, planar area
exhibited a significant decrease in the presence o f CAL 120 and returned promptly to control
values following its wash out (n = 3 independent preparations, a total of 5 osteoclasts).
Differences were assessed using a two-way ANOVA and Bonferroni's multiple comparisons
test. * indicatesp < 0.05 compared to vehicle at the corresponding times.
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prompting us to characterize effects o f selective inhibitors. Live osteoclasts were
monitored using time lapse phase-contrast microscopy. Freshly isolated rat osteoclasts
were bathed in HEPES-buffered M l99 supplemented with 15% FBS and 1% antibiotic
solution at 35°C and under control conditions, osteoclast lamellipodia were well spread
(0 min). Basal morphology and motility were recorded for 25 min before addition of
vehicle, wortmannin (1 pM), LY294002 (50 pM), GDC0941 (1 pM), PIK75 (1 pM),
TGX221 (1 pM), AS252424 (1 pM), IC87114 (1 pM) or CAL-120 (1 pM). Wortmannin
and CAL-120 (1 pM), but not vehicle, PIK75 or TGX221, caused prompt retraction of
lamellipodia at 10 min and 30 min (Fig. 2.2). See also Supplemental Videos 1 and 2,
showing representative appearance o f cells treated with vehicle (Suppl Video 1) or CAL120 (Suppl. Video 2) (see AVI files on accompanying CD, captions are in Appendix B).
Despite marked and sustained retraction, osteoclasts treated with GDC0941, IC87114 or
CAL-120 still remained motile, indicating that the cells were not quiescent as when
retraction is induced by wortmannin. Osteoclasts that were considered motile exhibited
pseudopod ruffling, while osteoclasts considered being quiescent had no pseudopod
ruffling.
To quantify the change in morphology, planar area of osteoclasts were measured
periodically over 60 min, with area expressed as a percentage of the mean area for each
cell before treatment. Within 10-15 min, GDC0941, LY294002, wortmannin, IC87114
and CAL-120 (Fig. 2.3E-I) induced significant retraction to 65-75% o f initial area. In
contrast, there was no significant response to TGX221, PIK75, AS252424 at 1 pM or
vehicle (Fig. 2.3A-E), consistent with the involvement o f a specific PI3K isoform in
regulating the osteoclast cytoskeleton.
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Some PI3K inhibitors are irreversible such as wortmannin (Wymann et al., 1996),
so we examined the reversibility o f the PI3K6 selective inhibitor, CAL-120 (Fig. 2.4A).
Planar area o f rat osteoclasts was measured periodically over 60 min, with area expressed
as a percentage o f the mean area for each cell before treatment. Following a control
period o f 10 min, vehicle, or CAL-120 (1 pM) was applied to the bath at 0 min and
washed out at 30 min (Fig. 2.4B). Vehicle caused no change in osteoclast planar area
before or after wash (Fig. 2.4Ai). In contrast, lamellipodia retracted in the presence of
CAL-120 with apparent re-spreading following wash (Fig. 2.4Aii). CAL-120 caused
significant retraction o f osteoclasts at 10 min and 15 min, followed by a return to baseline
after wash out. This demonstrates that the retraction is reversible and reveals a distinct
feature o f CAL-120. It should be noted that these studies involved lengthy time-lapse
recordings o f single osteoclasts precluding us from carrying out full concentrationdependence studies.
2.4.4

Inhibition of PI3K5 D isrupts Actin O rganization
We next investigated whether retraction o f lamellipodia was associated with

changes in the organization o f the actin cytoskeleton. In vitro, on non-mineralized
substrates, such as glass or plastic, osteoclasts form clusters podosomes, or a band of
podosomes at the periphery o f the cell, called F-actin belts. On mineralized substrates,
such as bone or calcium phosphate matrices, podosomal units condense, forming a ring in
the interior of the cell, called a sealing zone (Saltel et al., 2008). To examine the
disruption of F-actin belts and sealing zones, we quantified the proportion of cells with
complete or disrupted F-actin structures. The effects of selected class IA PI3K isoform
inhibitors were examined. PIK75, TGX221, CAL-120 or wortmannin were applied to
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Fig. 2.5. Effects o f PI3K inhibitors on actin belt organization in osteoclasts. Rat osteoclasts
were plated on FBS-coated glass coverslips in H C 0 3-buffered M l99 with FBS and
antibiotics. Samples were treated with vehicle or inhibitor for 10 min and then fixed. F-actin
was labeled using Alexa Fluor 488-conjugated phalloidin (green), nuclei were stained with
4',6-diamidino-2-phenylindole (DAPI, blue), and cells were examined by fluorescence
microscopy (40x objective, Zeiss Axio Observer Z l). Inhibitors were wortmannin
(wortmn), PIK75, TGX221 and CAL-120 (all 1 pM). Ai, Image shows a single untreated rat
osteoclast exhibiting a prominent F-actin belt at the cell periphery. Aiii and iv, F-actin belts
were also observed in osteoclasts treated with PIK75, TGX221. Aii and v, in contrast,
osteoclasts treated with wortmannin or CAL-120 for 10 min displayed a disorganized
pattern o f F-actin staining with clusters o f punctate structures. B, We quantified the number
o f osteoclasts exhibiting actin belts (encompassing at least 75% of the cell periphery).
Osteoclasts treated with wortmannin or CAL-120 displayed significantly fewer actin
beltsthan vehicle-treated cells, whereas PIK75 and TGX221 had no significant effect. Data
are the percentage o f osteoclasts exhibiting actin belts and are means ± S.E.M., n = 3
independent experiments with a total o f 1537 osteoclasts. Data were analyzed by one-way
ANOVA followed by Tukey's multiple comparisons test. * indicates p < 0.05 compared to
vehicle.
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Fig. 2.6. Time course o f PI3K5-selective inhibitor CAL-120 disruption of F-actin belt. Rat
osteoclasts were plated on FBS-coated glass coverslips in FIC03-buffered M l 99 with FBS
and antibiotics. Samples treated with vehicle (for 40 min) or CAL-120 (1 pM, for the times
indicated) and then fixed. F-actin was labeled using Alexa Fluor 488-conjugated phalloidin
(green). A, Representative images of actin belt organization were obtained using a Zeiss
LSM 510 META confocal microscope (63x objective). Osteoclast treated with vehicle only
for 40 min shows prominent F-actin belt at the cell periphery. In contrast, osteoclast treated
with CAL-120 for 20 min shows disorganized clusters of punctate F-actin containing
structures. B, The percentage o f osteoclasts exhibiting actin belts under each condition was
quantified using a Zeiss Axio Observer Z1 microscope (40x objective). Osteoclasts treated
with CAL-120 for up to 40 min displayed significantly fewer actin belts than vehicle-treated
cells. Data are the percentage of osteoclasts exhibiting actin belts and are means ± S.E.M., n
= 4 independent experiments with a total o f 1546 osteoclasts. Data were analyzed by one
way ANOVA followed by Tukey's multiple comparisons test. * indicatesp < 0.05 compared
to vehicle.
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Fig. 2.7. Live cell imaging of the effects o f CAL-120 on F-actin belt dynamics in rabbit
osteoclast expressing actin-EGFP. To directly observe the effects of the PI3K8-selective
inhibitor CAL-120 on F-actin belts rabbit osteoclasts were plated on FBS-coated MatTek
glass-bottom culture dishes and transduced with adenoviruses expressing actin-EGFP
fusion or EGFP proteins. Cells were then bathed in HEPES-buffered M l 19 medium with
15% FBS at ~26°C and imaged using confocal microscopy (40x objective, Zeiss LSM 510
META confocal microscope). Images labeled 0 min illustrate the appearance of osteoclasts
immediately prior to addition o f vehicle or CAL-120 (1 pM) to the bath. Ai, F-actin belt
remained intact in vehicle-treated osteoclast. Aii, CAL-120 induced gradual disappearance
o f the peripheral actin structures and an increase in actin fluorescence in the central region of
the osteoclast. Images are representative o f a total of 4 osteoclasts from 2 independent
preparations. B, Control samples transduced with EGFP protein alone showed uniform
distribution of fluorescence. See Supplemental Videos 4 & 5 of the responses illustrated in
panels Ai and Aii.
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Fig. 2.8. Effect o f PI3K8-selective inhibitor CAL-120 on sealing zone formation in
osteoclasts. Rat osteoclasts were plated on resorbable calcium phosphate-coated discs in
HCOj-buffered M l 99 with FBS and antibiotics. Samples were treated with vehicle or
CAL-120 (1 pM) for 10 min and then fixed. F-actin was labeled using Alexa Fluor 488conjugated phalloidin (green), nuclei were stained with DAPI (blue), and cells were
examined by fluorescence microscopy (40x objective, Zeiss Axio Observer.Zl). Ai,
Untreated osteoclast exhibits a prominent F-actin-rich sealing zone, characteristic o f active
osteoclasts on resorbable substrates. Note that sealing zones are more centrally located than
the peripheral actin belts illustrated in Figs. 6 & 7. Aii, osteoclasts treated with CAL-120
exhibited fewer sealing zones and displayed clusters of F-actin containing structures. B, We
quantified the number of osteoclasts exhibiting sealing zones. Osteoclasts treated CAL 120
displayed significantly fewer actin belts than vehicle-treated cells. Data are the percentage
o f osteoclasts exhibiting sealing zones and are means ± S.E.M., n = 3 independent
experiments with a total o f 592 osteoclasts. Data were analyzed by unpaired Student's t-test.
* indicatesp < 0 .05 compared to vehicle.
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osteoclasts for 10 min then cells were analyzed using fluorescence microscopy by an
individual blinded to the treatments (Fig. 2.5A). Wortmannin and CAL-120 caused a
significant reduction in the incidence o f F-actin belts in comparison to vehicle (Fig.
2.5B), whereas TGX221 and PIK75 had no significant effect (Fig. 2.5B). To determine
whether disruption o f F-actin belts is sustained in the continued presence o f CAL-120,
osteoclasts were treated with vehicle or CAL-120. CAL-120 treatment resulted in
disruption of the cytoskeletal organization compared to vehicle treated (Fig. 2.6A). In the
continued presence o f CAL-120, osteoclast F-actin cytoskeletal disruption was
maintained (Fig. 2.6B). To complement these studies we examined the effect o f CAL-120
on F-actin belts in live cells using rabbit osteoclasts virally transduced with EGFP-actin.
When viewed using confocal microscopy, vehicle treatment caused no change in F-actin
belt organization (Fig. 2.7Ai). In contrast, CAL-120 gradually induced disruption o f Factin belt organization starting within 10 min (Fig. 2.7Aii). See also Supplemental Videos
3 and 4, showing representative appearance o f cells treated with vehicle (Suppl. Video 3)
or CAL-120 (Suppl. Video 4) (see AVI files on accompanying CD, captions are in
Appendix B).
To examine sealing zones, rat osteoclasts were plated on coverslips coated with
resorbable calcium phosphate (BD BioCoat

T'K /f

Osteologic

TIV/f

), treated with vehicle, or

CAL-120 (1 pM) for 10 min, fixed, permeabilized and incubated with fluorescently
tagged phalloidin (Fig. 2.8A). Notably, sealing zones generally had a smaller diameter
than F-actin belts. Vehicle treatment yielded 40% of cells with sealing zones, where as
CAL-120 treatment reduced the incidence o f intact sealing zones to 10% o f cells. To
examine the disruption o f sealing zones, we used the same protocol as quantifying F-actin
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belts. CAL-120 caused a significant reduction in the number of actin rings in comparison
to vehicle (Fig. 2.8B). It was determined that the PI3K8 inhibitor, CAL-120 decreases the
incidence o f osteoclasts with sealing zones, consistent with the involvement o f a specific
PI3K isoform in regulating cytoskeletal remodeling in osteoclasts.
2.4.5

Inhibition of PI3K Suppresses the Effects of RANKL on Osteoclast Survival
Bone resorption is proportional to the number o f osteoclasts present during any

given time, and therefore, survival is a key factor that regulates bone loss in vivo
(Manolagas, 2000). Therefore, we examined the effect o f isoform-selective PI3K
inhibitors on osteoclast survival. Rat osteoclasts were placed on FBS-coated coverslips
and incubated the absence (control) or presence o f RANKL (100 ng/ml), along with
vehicle, 1 pM CAL-120, 1 pM TGX221 or 100 nM PIK75. Survival was quantified by
counting the number o f osteoclasts before and after an 18 h incubation period and the
proportion o f surviving cells was calculated. Osteoclasts were identified by phasecontrast microscopy as multinucleated cells (> 3 nuclei). There were no significant
effects o f inhibitors on survival under control conditions (Fig. 2.9). However, RANKL
significantly enhanced osteoclast survival, and CAL-120, TGX221 and PIK75 suppressed
the stimulatory effect of RANKL on survival. These data illustrate a key functional role
for PI3K in mediating the effects o f RANKL on osteoclast survival.
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Fig. 2.9. The effects o f isoform-selective PI3K inhibitors on osteoclast survival. Rat
osteoclasts were plated on coverslips in H C 03-buffered M 199 with 15% FBS and antibiotics.
As indicated, samples were treated with RANKL (100 ng/ml) or its vehicle (Control). In
addition, samples were treated with vehicle, PIK75 (100 nM), TGX221 (1 pM) or CAL-120
(1 pM). Survival was assessed by counting (using phase-contrast microscopy) the number of
osteoclasts before and after 18 h o f culture. As expected, RANKL increased osteoclast
survival compared to vehicle. In contrast to their selective effects on cytoskeletal
organization, all inhibitors tested (PIK75, TGX221 and CAL-120) suppressed RANKLinduced survival. Data are the number o f surviving osteoclasts on each coverslip at 18 h
expressed as a percentage o f the initial number of osteoclasts on the same coverslip (means ±
S.E.M., n = 3 independent experiments with a total o f 2529 osteoclasts). Data were analyzed
by a two-way ANOVA followed by a Bonferroni's multiple comparisons test. * indicates p <
0.05 for the effect o f RANKL.
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2.5

Discussion
In the present study, we characterized a new potent and selective PI3K8 inhibitor

as well as determined new insights into the roles o f PI3K isoforms in regulating
osteoclast function. New findings reported include the potency and specificity o f a novel
PI3K8 inhibitor, CAL-120, as well as the effects of isoform-selective PI3K inhibitors on
1) the viability o f RAW 264.7 cells, 2) osteoclast cytoskeletal organization, and 3)
osteoclast survival. A summary o f these findings can be found in Table 1. For the first
time, we demonstrate that PI3K8 plays a central role in osteoclast morphology and
cytoskeletal reorganization, and that PI3Ka, PI3K(3 and PI3K8 all contribute to osteoclast
RANKL-induced survival. Finally, we reported the IC50 and EC 50 values o f CAL-120, a
potent, reversible and selective cell permeable inhibitor of PI3K8. The other PI3K
inhibitors used in the present study have been characterized previously (Marone et al.,
2008).
The expression o f mRNA encoding PI3K isoforms has been documented in
monocyte-macrophage-like RAW 264.7 cells with levels from highest to lowest being
PI3Ka, PI3K8 and then PI3KP (PI3Ky not examined) (Grey et al., 2010). Since
osteoclasts are isolated with a number o f other cell types, it is difficult to accurately
determine the expression levels of PI3K in authentic osteoclasts. The finding that PI3K8
expression is high in cells o f hematopoietic lineage (Chantry et al., 1997) suggests that
the 8 isoform may serve important function in osteoclasts.
Genetically modified mice, generated either by deletion of PI3K p i 108 or by
mutation of the kinase domain, exhibit severely altered immune and inflammatory
responses compared to their wild-type controls (Vanhaesebroeck et al., 2005). For
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PI3K In h ibitor

T arget

PIK75
TGX221
AS252424
CAL-120
Wortmannin

a

Prom ote
R etraction

D isrupt
F-actin Belts

-

-

p

-

-

y
8
Pan-PI3K

-

+
4*

n/t
+
+

Suppress
Survival
4+
n/t
+
n/t

Table 2.2. Summary of findings. + symbol represents positive, - symbol represents a
negative and n/t represents not tested. Wortmannin, LY294002, CAL-120, GDC0941 and
IC87114 induced osteoclast retraction, whereas TGX221, PIK75 and AS242525 did not,
consistent with involvement of the PI3K8 isoform in regulating cytoskeletal remodeling
in osteoclasts. CAL-120 and wortmannin, but not TGX221 and PIK75, disrupted F-actin
belts which are important for osteoclast function. Further, CAL-120 decreased sealing
zone number in osteoclasts on calcium phosphate surfaces. CAL-120, TGX221 and
PIK75 all suppressed RANKL-induced osteoclast survival. In conclusion, these data are
consistent with a key role for the PI3K8 in regulating osteoclast morphology and
cytoskeletal function. In contrast, a non-redundant role of Class LA PI3K isoforms was
observed in osteoclast survival.
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instance, studies of mice with a loss o f function genetic alteration in the PI3K5 subunit
exhibit defects in B- and T-cell signaling, including improper maturation, defective
antigen receptor signaling, and impaired humoral immune responses (Ramadani et al.,
2010; Uno et al., 2010). Recent data in macrophages demonstrate that PI3K5 is localized
around the Golgi membrane and seems to be important in vesicle trafficking (Low et a l,
2010). Moreover, inhibition o f PI3K8 in neutrophils leads to defects in chemotaxis
(Afonso & Parent, 2010). Our study is the first to establish roles for PI3K8 in osteoclast
survival and function.
PI3K has been shown to participate in lamellipodia spreading of osteoclasts
(Palacio & Felix, 2001) and other cell types (Di Marzio et al., 2005; Bagorda et al., 2006;
Weiger et al., 2009). The results o f our study show that blocking PI3K.5
pharmacologically causes retraction o f osteoclast lamellipodia; at the same time,
peripheral pseudopod ruffling is maintained. PI3K signaling might initiate osteoclast
spreading through interactions with other signaling pathways, including Rho, Rac and
Cdc42. It has been shown by others that activation of Rho and inhibition of Rac induces
retraction of macrophage-derived multinucleated cells (Ory et al., 2000). In keeping with
this idea, RhoA and Rac have been shown to be regulated negatively and positively by
PI3K8, respectively (Eickholt et al., 2007; Papakonstanti et al., 2008). Consistent with
our findings, others have shown acute morphological contraction in macrophages upon
PI3K8 inactivation observed in parallel with decreased Rac activity and increased Rho
activity (Papakonstanti et al., 2007). Therefore, it would be o f interest in future studies to
examine the possible role o f Rho and Rac in mediating the lamellipod retraction elicited
by blocking PI3K5 in osteoclasts.
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Osteoclast retraction is also caused by the hormone calcitonin, and by the
bioactive lipid mediators lysophosphatidic acid (LPA) and platelet-activating factor
(PAF) which signal through GPCRs (Wood et al., 1991; Gravel et al., 1994; Lapierre et
al., 2010). Specifically, calcitonin-induced retraction of lamellipodia is sustained while
osteoclasts remain quiescent (Komarova et al., 2003), whereas LPA-induced retraction of
lamellipodia is sustained and peripheral pseudopod ruffling is sustained (Lapierre et al.,
2010). Furthermore, PAF-induced retraction o f osteoclast lamellipodia is not sustained
over time resulting in re-spreading of lamellipodia (Wood et al., 1991). Interestingly, the
morphological responses observed during inactivation o f PI3K8 are similar to LPAinduced retraction and distinct from the responses elicited by calcitonin and PAF. Further
studies are required to determine if there is possible cross-talk between LPA signaling
and PI3K8 signaling. In the present study, we found that TGX221 induced partial
retraction of osteoclasts. TGX221 is a potent and selective cell permeable inhibitor of
PI3K pllOp relative to all other PI3K isoforms except PI3K8 (IC5 0 values: pi 10a 1000
nM; pllOp 9 nM; pi 108 210 nM) (Jackson et al., 2005). Likely, the concentration used
in our study (1 pM) fully inhibits PI3KP and partially blocks PI3K8 accounting for its
effect on retraction.
Activation o f the avP3 integrin in osteoclasts initiates a signaling cascade which
is known to involve a c-Src, Pyk2 and c-Cbl complex, and PI3K, resulting in actin
polymerization and cytoskeletal reorganization (Chellaiah & Hruska, 1996; Faccio et al.,
2002; Novack & Faccio, 2009). Since osteoclasts lacking P3 have an abnormal
cytoskeleton, fail to spread and do not have sealing zones in vitro (McHugh et al., 2000),
it is possible that avp3 integrins are required to activate PI3K8 to mediate its effects on
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the cytoskeleton. Further study is needed in order to elucidate the possible association of
PI3K isoforms and avp3 integrins.
Mature osteoclasts exhibit two types o f specialized actin structures, F-actin belts
and sealing zones, when adherent to non-mineralized or mineralized substrata,
respectively. It is suggested that osteoclasts only degrade substrate within the area
defined by specialized actin structures (Badowski et a l, 2008) and, therefore, bone
resorption by osteoclasts is dependent on the integrity of the actin cytoskeleton (Jurdic et
al., 2006; Ory et al., 2008). The results from our study show that the incidence o f F-actin
belts and sealing zones in osteoclasts is markedly lower when PI3K8 is inhibited. Live
cell imaging on osteoclasts shows gradual disruption o f F-actin belts into puncta along
with break down o f actin structures. This finding is in accordance with the observation
that inhibition of PI3K disrupts ring-like F-actin structures in murine osteoclast-like cells
(Nakamura et al., 1995; Lakkakorpi et al., 1997). Our results indicate that PI3K p i 108
inhibition causes both retraction and disruption of F-actin belts and sealing zones,
suggesting that the two events are correlated. However, as discussed previously, the exact
mechanisms by which PI3K affects the actin cytoskeleton are currently unknown. Rho
and Rac have an antagonistic relationship affecting cell spreading, and both have been
implicated in regulating the formation of F-actin belts and sealing zones (Razzouk et al.,
1999; Chellaiah et al., 2000; Ory et al., 2008). Specifically, a constitutively activated
form o f Rho stimulates gelsolin-associated PI3K activity resulting in podosome assembly
in osteoclasts (Chellaiah et al., 2000). F-actin belts and sealing zones have been shown to
regulate contractility o f osteoclasts adherent to non-mineralized or mineralized
substratum in part through myosin II (Chabadel et al., 2007). Furthermore, compounds
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that affect osteoclast retraction also disrupt sealing zones and the ability of osteoclasts to
form pits on dentine slices, such as the hormone calcitonin (Suzuki et al., 1996;
Yamamoto et al., 2006).
The lifespan o f osteoclast precursors and mature osteoclasts, in conjunction with
their differentiation and activation, contribute to the control o f bone resorption
(Manolagas, 2000). Several ligands may activate PI3K and regulate osteoclast survival.
For example, in previous studies, RANKL has been shown to activate PI3K/Akt/mTOR
signaling pathway, thereby enhancing osteoclast survival (Glantschnig et al., 2003;
Aeschlimann & Evans, 2004). RANKL also activates NF-kB signaling and activation of
calcineurin and NFA Tcl, promoting osteoclastogenesis and enhancing cell survival
(Aeschlimann & Evans, 2004; Novack & Teitelbaum, 2008). According to our results, all
Class IA PI3K isoforms play a role in regulating RANKL-induced cell survival, but do
not affect basal levels o f survival. In support o f our findings, others have shown that the
activity o f any Class IA PI3K isoform can sustain survival of other cell types (Foukas et
al., 2010). Specifically, leukocytes and fibroblasts continue to proliferate and survive
during PI3K0a or PI3K8 inactivation by increasing pi 1Op signaling and enhancing input
from the ERK pathway (Foukas et al., 2010). Similar results in embryonic fibroblasts
show that PI3K a or PI3K(3 alone can sustain cell proliferation and survival (Foukas et al.,
2010; Matheny & Adamo, 2010). These data demonstrate functional redundancy o f PI3K
isoforms and that only a small subset o f Class IA PI3K activity is necessary for osteoclast
survival. In contrast, it has been suggested that PI3Ka is most important for the survival
of other cell types (Niedermeier et al., 2009).
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Overall, our findings provide evidence for redundant and non-redundant functions
o f different PI3K isoforms and show for the first time an important role for PI3K5 in
regulating osteoclast morphology and cytoskeletal function. Knowledge of the important
roles

o f each

Class

I

PI3K

family

member

in

various

physiological

and

pathophysiological processes may allow isoform-selective PI3K inhibitors to be used
therapeutically.

In particular, the PI3K5 isoform, which has more limited tissue

distribution than PI3K a and PI3K0 is an attractive target for novel anti-resorptive
therapeutics.
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General Discussion

80

3.1

Summary and Conclusions

Objective #1: To characterize the effects o f isoform-selective PI3K inhibitors on the
viability o f monocyte-macrophage-like cells.
Effects o f isoform-selective PI3K inhibitors on the viability of RAW 264.7 cells
were investigated using an MTT assay. High concentrations of PIK75 and LY294002
decreased viability, whereas GDC0941, TGX221, CAL-120, IC87114, AS252424 and
wortmannin had no significant effects.

Objective #2: To investigate the effects o f isoform-selective PI3K inhibitors on osteoclast
morphology and motility.
Live cell microscopy revealed that inhibition of the PI3K8 isoform induces
retraction o f lamellipodia in primary rat osteoclasts under basal conditions. Although
lamellipodia retracted, peripheral pseudopods still remained motile.

Objective #3: To determine the effect o f isoform-selective PI3K inhibitors on cytoskeletal
organization in osteoclasts on varying substrata.
Fluorescence microscopy revealed that the PI3K8 isoform is important in F-actin
organization in rat primary osteoclasts plated on glass and on calcium phosphate surfaces.

Objective #4: To evaluate the effect o f isoform-selective PI3K inhibitors on osteoclast
survival.
All isoform-selective Class LA PI3K inhibitors suppressed RANKL-induced
survival.
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3.2

Contributions of the Research to the Current State of Knowledge
General significance—Prior to the work reported in this thesis, knowledge of the

effects o f isoform-selective PI3K inhibitors on osteoclasts was limited. The overall
objective o f this research was to investigate the effect of isoform-selective PI3K
inhibitors in osteoclasts. The key implication of this study is that PI3K5 plays an
important role in regulating osteoclast morphology and cytoskeletal organization;
whereas, multiple PI3K isoforms contribute to the control of osteoclast survival. Thus,
the PI3K5 isoform, which has more limited tissue distribution than PI3Ka and PI3KP, is
an attractive target for reducing bone loss in diseases, such as metastatic bone cancer and
inflammatory bone diseases.
Cancer metastasis and osteolytic lesions— Common human cancers, including
lung, prostate and breast often metastasize to bone due to its blood vessel density and
abundance o f growth factors, which support the invasion and proliferation of cancer cells
(Mundy, 2002). Tumours in bone frequently promote the formation and activation of
osteoclasts, leading to bone resorption and subsequent tumour growth. Cancer cell
proliferation in bone mainly occurs because osteoclastic resorption releases growth
factors from the matrix, such as IGF-1, TGFp, fibroblast growth factor and plateletderived growth factor (Mohan & Baylink, 1991; Mundy, 2002, Kingsley, 2007 #97).
Interestingly, all o f the above growth factors signal through receptor tyrosine kinases,
which directly or indirectly activate the PBK/Akt pathway (Brader & Eccles, 2004; Stitt
et al., 2004; Assinder et al., 2009). Furthermore, tumor progression is often associated
with excessive activation of the PI3K pathway, whether it is due to activating mutations
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of the PI3K catalytic p i 10 subunit, regulatory p85 subunit, or deletion o f the PTEN
inhibitory protein (Liu et a l, 2009; Vanhaesebroeck et a l, 2010).
There is extensive evidence that the PI3K pathway affects osteoclast survival, in
particular through RANKL signaling (Yang et a l, 2008; Yi et a l, 2008). Tumour cells
release factors which act on neighbouring cells (such as T cells or osteoblasts) to release
RANKL. In turn, RANKL binds RANK receptors expressed on tumour cells which
promote migration and proliferation (Huang et a l, 2002; Jones et a l, 2006). As
mentioned above, RANKL also binds to RANK on osteoclasts to promote bone
resorption and the release of bone-derived growth factors.
Recently developed isoform-selective PI3K inhibitors show considerable promise
for the treatment o f cancer and are making their way into the early phases of clinical trials
(Lannutti et a l, 2011). The findings in Chapter Two suggest a novel therapy for skeletal
métastasés - it may be possible to identify isoform-selective PI3K inhibitors that suppress
metastatic tumour cell growth, as well as inhibit bone resorption. Thus, pharmacological
inhibition of the PI3K signaling axis may reduce tumor proliferation in bone, and limit
the progression o f osteolytic lesions.
PI3K and inflammatory bone diseases— Patients suffering from arthritis have a
marked decrease in quality o f life. For example, rheumatoid arthritis (RA) is a chronic,
progressive, debilitating inflammatory disease that affects approximately 1% of the
world’s population (Rommel et a l, 2007). Matrix-degrading enzymes such as
metalloproteinases were initially thought to be the sole cause o f bone and cartilage
destruction in arthritis. However, cell-mediated mechanisms, involving osteoclast
activation, are now thought to be important contributors (Takayanagi, 2009).
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Identification o f osteoclast-like giant cells at the interface between the synovium and
bone in rheumatoid joints dates back to the early 1980’s (Takayanagi, 2009). It has been
determined that osteoclasts are responsible for the resorption of mineralized extracellular
tissue, which contributes to the damage, pain and deformity associated with RA (Schett,
2008). In the pathogenesis of bone destruction associated with RA, the synovium is a site
o f active interplay between immune and bone cells. Furthermore, RA synovial fluid
contains osteoclast precursors as well as cells that support osteoclastogenesis
(Takayanagi, 2009). It is important that osteoclast activity be tightly regulated for skeletal
and joint homeostasis. Osteoclast activation and apoptosis represents a critical point at
which bone resorption can be minimized during RA. In osteoclasts, PI3K is activated by
RANKL and MCSF, two cytokines that are critical in osteoclast development (Novack &
Teitelbaum, 2008; Mandal etal., 2009).
Interestingly, selective PI3K8 and PI3Ky inhibitors suppress joint inflammation
and bone erosion in mouse and rat RA models (Rommel et al., 2007). Evidence so far
suggests that PI3K5 and PI3Ky operate as partners in distinct, yet co-dependent signaling
pathways in many immune cells, such as B cells, T cells, macrophages and mast cells
(Rommel et al., 2007). This strongly indicates that, in addition to RA, these enzymes are
potential therapeutic targets for inflammatory disease. Therefore, it is possible that
isoform-selective PI3K inhibitors may be useful for the treatment o f inflammatory bone
diseases such as RA by suppressing the inflammatory response and inhibiting osteoclast
activity.
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3.3

Limitations of the Research and Suggestions for Future Studies
In vitro experiments - In vitro studies are important for understanding the

mechanisms o f cell physiology. The main advantages o f in vitro experiments are that they
allow for the precise control of concentrations of studied compounds and that results are
usually swift. In vitro studies do have their limitations, such as culture artifacts. However,
it is difficult to monitor the activity of PI3Ks in cells in situ (Vanhaesebroeck et al.,
2005).
Pharmacological inhibitors were used in determining the roles o f PI3K isoforms
in osteoclasts and it is possible that inhibitors had non-specific effects. It would have
been ideal to perform full concentration-response studies for the effects o f inhibitors on
the morphology o f primary osteoclasts. However, it should be noted that these studies
involve lengthy time-lapse recordings of single osteoclasts, precluding us from carrying
out full concentration-dependence studies. It would be desirable to validate the findings
in Chapter Two using knockdown techniques such as shRNA targeting PI3K8, or by
obtaining osteoclasts from PI3K8 ‘knockout’ or ‘kinase-deficient knock in’ mice.
Moreover, studies o f such genetically modified mice would allow for determination of a
bone phenotype, which has not yet been documented. Further study is needed to elucidate
the possible effects o f genetic modification o f PI3K isoforms on the skeleton in vivo.

Another limitation o f the present studies is the possibility that contaminating cell
types may release signaling factors that act on osteoclasts and, thus, produce indirect
effects in response to PI3K inhibitors.
A number o f questions remain. These include: whether certain PI3K isoforms
produce specific pools o f PIP3 located on the plasma membrane, endosomes (Sato et al.,
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2003) or nucleus (Lindsay et al., 2006); and whether PI3K isoforms interact with other
proteins. The roles o f many phosphatases that regulate and diversify PI3K signaling are
undetermined and further complicate the situation. Future investigations should include
lipid analysis, for instance by mass spectrometry, to study the phospholipid profile in
primary cells (Vanhaesebroeck et al., 2005).
RAW 264.7 cells (rather than primary osteoclasts) were selected for Objective #1
because they are an osteoclast precursor cell model and because primary cultures of
osteoclasts always include other cell types.
PI3K signaling in osteoclasts - The data presented in Chapter Two do not fully
explain the PI3K signaling pathway and the ligands which activate it. Further studies are
required to determine the mechanisms leading to retraction o f osteoclast lamellipodia and
the influence of PI3K5, as well as the signaling pathways in which multiple PI3K
isoforms decrease osteoclast survival.
Suggestions for future work include determining the relative expression levels of
the different PI3K isoforms in osteoclasts but, as mentioned above, it is difficult to obtain
pure preparations o f osteoclasts. The purest system presently available is probably
osteoclasts differentiated from bone marrow cell cultures. Using pharmacological
approaches, we have identified important roles for specific PI3K isoforms in osteoclasts.
However, we have not yet determined whether this is due to differences in i) the
expression of these isoforms, ii) their intrinsic biochemical activity, or iii) their
localization within the osteoclast. Further studies are clearly needed.
PI3K signaling in osteoclastogenesis - RANKL-RANK-mediated interaction
activates tumour necrosis factor receptor-associated factor 6 (TRAF 6 ), c-src and PI3K
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and later c-fos, NF- kB and NFATcl to drive osteoclastogenesis (Aeschlimann & Evans,
2004). The importance of c-fos, NF- kB and NFATcl

in osteoclastogenesis is

demonstrated in knockout mice of each signaling molecule - all o f which exhibit
osteopetrosis (Grigoriadis et al., 1994; Asagiri & Takayanagi, 2007). A recent study by
Kang and colleagues report that genetic inactivation of the p llO y gene leads to an
increase in bone mass, likely due to impairment in osteoclastogenesis (Kang et al., 2010).
PI3K pllO y and p i 105 have been shown to activate NF-kB in other cell types so it is
plausible that they could be having an effect on osteoclast precursors (Wang et al., 2011).
It would be interesting to know the bone phenotype produced by a p i 108 knock out and
the effects p i 105 have on c-fos, NF-kB and NFATcl expression. The mice have been
generated but the effect on the skeleton has not yet been documented. It is possible that
PI3K p i 10 plays a role in osteoclastogenesis, and further studies are required to
investigate this process.
PI3K signaling in osteoclast survival and apoptosis - It will be o f interest to
extend our studies o f osteoclast survival by looking at the effects of isoform-selective
PI3K inhibitors on apoptosis. Apoptosis normally controls and regulates excessive
proliferation and damage to cells by eliminating them (Chang et al., 2003). When
apoptosis is compromised, cell survival is prolonged and problems such as cancer can
arise. The Bcl-2 family of proteins plays a critical role in the regulation of apoptosis.
These proteins include both pro-apoptotic proteins such as, BAD and BAX as well as
anti-apoptotic proteins such as Bcl-2 and Bcl-xi (Chang et al., 2003). The balance of antiapoptotic and pro-apoptotic proteins is thought to dictate whether or not a cell will
survive or undergo apoptosis. Stimulation o f PI3K leads to activation of Akt, which has
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been shown to increase cell survival in response to IGF-1 (Vivanco & Sawyers, 2002).
Also, constitutively active Akt rescues cells during PTEN-mediated apoptosis (Li et al.,
1998). There are several possible mechanisms by which Akt may protect cells from
apoptosis: i) phosphorylation of the pro-apoptotic protein BAD, which causes its
dissociation from anti-apoptotic protein BCL-xi (normally, BAD forms a non-functional
heterodimer with the BCL-xj (Vivanco & Sawyers, 2002)); ii) phosphorylation of the proapoptotic protease, caspase-9, inhibiting catalytic activity (Cardone et a l, 1998); and iii)
phosphorylation o f the Forkhead family o f transcription factors, which inhibits
translocation into the nucleus (Forkhead transcription factors normally cause upregulation of several pro-apoptotic proteins such as FAS ligand (Vivanco & Sawyers,
2002)). Future studies should include apoptosis assays to determine the effect of PI3K
inhibitors on osteoclast apoptosis. To elucidate the mechanism, it would be interesting to
look at expression levels of anti-apoptotic proteins such as Bcl-2 or Bcl-xi, or proapoptotic proteins such as caspase-9 during blockade or inactivation of specific PI3K
isoforms.
In summary, for the first time, we have described the potency and specificity of a
novel PI3K8 inhibitor, CAL-120. We also demonstrate the effects of isoform-selective
PI3K inhibitors on the viability of RAW 264.7 cells and on the cytoskeletal organization
and survival of primary osteoclasts. For the first time, we demonstrate that PI3K5 plays a
central role in regulating osteoclast morphology and cytoskeletal organization, and that
PI3Ka, P and 5 all contribute to RANKL-induced survival. PI3Ks are promising targets
for therapeutic intervention in metabolic, immunological and oncological diseases
(Vanhaesebroeck et al., 2010). Interference with PI3K signaling should be targeted at a
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specific PI3K isoform to reduce side-effects. The potential exists for identifying isoformselective PI3K inhibitors that target both osteoclasts and tumor cells for the treatment of
metastatic bone disease, or osteoclasts and immune cells for the treatment of
inflammatory diseases such as RA. In particular, PI3K8, which has more limited tissue
distribution than PI3K a and PI3KP is an attractive target for the future development of
anti-resorptive therapeutics.
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Supplementary Video Captions
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Suppl. Video 1. No Effect of Vehicle on Osteoclast Morphology or Motility. Rat
osteoclasts were bathed in HEPES-buffered M l99 medium with 15% FBS medium at
35°C and imaged using time-lapse phase-contrast microscopy. Video begins at 0 min,
vehicle was added at 24 min and video ends at 60 min. Image intervals are 1 min and
frames are shown at 10 frames/s. Vehicle was added ~ 2 s into the video. Width of field is
320 pm. Selected frames from this video are shown in Fig. 2.2A.
Suppl. Video 2. PI3K8 Isoform-Selective Inhibitor, CAL-120. Induces Osteoclast
Retraction Without Inhibiting Pseudopod Motility. Rat osteoclasts were bathed in
HEPES-buffered M l99 medium with 15% FBS medium at 35°C and imaged using timelapse phase-contrast microscopy. Video begins at 0 min, CAL-120 (1 pM) was added at
24 min and video ends at 60 min. Image intervals are 1 min and frames are shown at 10
frames/s. CAL-120 was added 2 s into the video. Width of field is 320 pm. Selected
frames from this video are shown in Fig. 2.2E.
Suppl. Video 3. No Effect o f Vehicle on Actin Organization in Osteoclasts. Rabbit
osteoclasts were plated on FBS-coated MatTek glass-bottom culture dishes and
transduced with adenoviruses expressing actin-EGFP fusion. Cells were then bathed in
HEPES-buffered M l99 medium with 15% FBS at ~26°C and imaged using confocal
microscopy. Video begins at 0 min, vehicle was added at 7.5 min and video ends at 90
min. Image intervals are 1.5 min and frames are shown at 12 frames/s. CAL-120 was
added at immediately into the video. Width o f the field is 225 pm. Data obtained from
this video are included in Fig. 2.7Ai.
Suppl. Video 4. PI3K8 Isoform-Selective Inhibitor, CAL-120 Disrupts Actin
Organization in Osteoclasts. Rabbit osteoclasts were plated on FBS-coated MatTek glassbottom culture dishes and transduced with adenoviruses expressing actin-EGFP fusion.
Cells were then bathed in HEPES-buffered M l99 medium with 15% FBS at ~26°C and
imaged using confocal microscopy. Video begins at 0 min, CAL 120 (1 pM) was added at
7.5 min and video ends at 90 min. Image intervals are 1.5 min and frames are shown at
12 frames/s. CAL120 was added at immediately into the video. Width of the field is 225
pm. Data obtained from this video are included in Fig. 2.7Aii.

